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Patient compliance is very important and highly depends on the drug dosage form which 
correlates with the success of therapy. Drug delivery systems can be adapted to different 
pharmaceutical ingredients and to different delivery routes depending on the application. This 
thesis focuses on the development and characterization of different types of drug delivery systems 
with a focus on stimuli-responsive biomaterials. Stimuli-responsive biomaterials are a promising 
approach for achieving on-demand drug release. They are intended to deliver their active 
compound at the appropriate time and site of action in response to specific triggers. The aim of 
this thesis was the development and characterization of a pH-responsive intravaginal ring (IVR) 
and a thermo-responsive wound dressing. The IVR is intended for the prevention of HIV infection 
while the wound dressing is to treat chronic wounds that develop as a co-morbidity associated with 
immune-compromised patients.  
The behavior of polyvinyl alcohol (PVA) films containing nanoparticles (NPs) for vaginal 
drug delivery was evaluated first.  In this study, we demonstrated that the amount of NPs had little 
effect on film dissolution and on the storage and loss modulus. However, the percentage of PVA 
used and the amount of plasticizer (polyethylene glycol) and carrageenan (a film forming agent) 
greatly affected the physico-mechanical properties of the film and play an important role in film 
dissolution time and nanoparticle (NP) release.  
         Secondly, we fabricated an IVR with polyurethane HP-60D-35 containing 
hydroxychloroquine (HCQ) as a prevention strategy against HIV. The safety of the IVR and HCQ 
were assessed on the vaginal epithelial cells VK2/E6E7, the ecto-cervical cells ECT1 and more 
importantly, on vaginal normal microflora lactobacillus crispatus and jensenii. No significant 
viii 
 
toxicity was observed.  
          We then designed a segmented IVR with half of the ring delivering HCQ while the second-
half was coated with a pH-responsive polymer to deliver anti-CCR5 siRNA NPs. HCQ was 
released continuously for over 25 days with a mean daily release of 31.17±3.06 µg/mL. Anti-
CCR5 siRNA NPs were released from the pH-responsive coated segment only when the pH was 
7.3  (e.g. in the presence of simulated seminal fluid) with a total release of 5.12 ±0.9 mg compared 
to vaginal fluid simulant alone (0.42 ±0.19 mg). Anti-CCR5 siRNA NPs knocked down CCR5 
gene expression by 83±5.1% in vitro in the CD4+ T-cell line Sup-T1.   
           In the second part of the thesis, we made a thermo-responsive wound dressing using gelatin 
crosslinked with chitosan. LL37 and vancomycin were encapsulated into solid lipid nanoparticles 
(SLN) and mixed into the gelatin-chitosan hydrogel. The hydrogel itself liquefied rapidly (30min) 
at 33ºC (human skin temperature) than at room temperature (remained semisolid).  We evaluated 
LL37/vancomycin-SLN using a microtiter plate-based biofilm assay formed using S. aureus. 
6mg/mL of LL37/vancomycin was capable of significantly reducing S. aureus biomass.  
Overall, the development of stimuli-responsive drug delivery systems is appealing as it can release 
drugs only when needed, which will reduce toxicity and unwanted side-effects. Furthermore, it 
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The first part of the introduction was adapted from the following scientific article:  
Yannick Traore, Yufei Chen, Emmanuel A. Ho Clinical Pharmacology & Therapeutics, 

















1.1. HIV infection 
 Human immunodeficiency virus 
Human immunodeficiency virus (HIV) keeps spreading among vulnerable and resource-
limited populations worldwide. HIV is an enveloped lentivirus, member of the family retroviridae 
[1], and replicates using reverse transcription. HIV-1 and HIV-2 are two closely related but 
different strains of HIV that can induce acquired immunodeficiency syndrome (AIDS). Both 
originate from the parent virus simian immunodeficiency virus (SIV) [2].  HIV-1 and HIV-2 share 
30-60 % of their genome but have comparable genomic organization [3]. They have similar 
transmission routes and the capacity to bind CD4 molecules on immune cells, but HIV-2 infection 
is much slower than HIV-1 [4]. HIV-2 is much less virulent hence bearing the definition of long-
term non-progressors disease that keeps the viral load under the limit of detection [5]. The CD4 T 
cell counts are maintained in the normal range for decades, and less CD4 T cell activation has been 
reported in HIV-2 patients [6, 7]. The resistance of dendritic cells and the reduced rate of 
replication in macrophages may explain the moderate infection of HIV-2 compared to HIV-1 [8]. 
The focus of this thesis will be on HIV-1, the most common virus found in HIV-positive patients. 
HIV-1 infection originated in Central Africa [9].  HIV-1 is subdivided into different groups listed 
as M, N, O, and P. The most virulent group is the M which is further subdivided and represented 
by the letters A to K [10]. HIV-1 spreads by sexual intercourse, neonatal and percutaneous routes. 
More than 80% of adults infected by HIV-1 occur sexually, thus making sexual intercourse the 






 Epidemiology  
It has been estimated that in 2019, more than 38 million people lived with HIV in the world. 
Approximately 96% of people that acquired HIV-1 infection live in developing countries [12]. 
Many efforts have been made to further reduce the infection rate in the past decade, but still, around 
690 000 people died from HIV in 2019 [12]. Those numbers are not negligible, so many efforts 
have to be made to further decrease HIV incidence in the world. Investigations into sub-Saharan 
Africa revealed that there is a decrease in condom usage, but an increase in sexual intercourse 
among young people [13]. There was also no reduction in the transmission of HIV among sex 
workers or in homosexual partners over time [13]. Sexual intercourse is the most common HIV 
transmission route with injection drug users being second. For example, in Asia, more than 28% 
of HIV-infected people are drug users [13]. A lot of effort must be done to reduce HIV incidence. 
 
 HIV transmission  
HIV-1 utilizes three major infection routes including sexual contact across mucosal 
surfaces, mother-to-infant transmission and percutaneous inoculation [14]. Heterosexual 
transmission accounts for more than 70% of HIV infection, which is much greater than men having 
sex with men and mother-to-child infections [14]. The genital and the gastrointestinal tract are the 
primary infection sites for HIV. They are rich in HIV target cells such as primary T cells, dendritic 
cells and macrophages [11]. The female genital tract (FGT) and the ectocervix offer a larger 
surface area that provides more possibility for HIV entry even though the squamous epithelium 
layers that cover their surface offer a tremendous physical barrier against HIV entry. The 
endocervix constitutes only one layer of columnar epithelium and will allow easy passage of the 
virus. There is an abundant population of T-cells in the junction where the ectocervix transitions 
into the endocervix, offering an ideal site for virus entry [15]. The upper vaginal tract may become 
4 
 
more susceptible to HIV penetration during ovulation marked by an increase in estrogen level [15]. 
The mucus present in FGT is intended to block the virus movement, but this can also present as a 
downside by keeping the virus longer within the vaginal tract increasing infection [16]. Free HIV 
virion released into the mucosa by an infected donor crosses the epithelial barrier by transcytosis, 
endocytosis, followed by exocytosis. A free virion can also penetrate through the gaps between 
epithelial cells causing an active infection. Even though HIV has more affinity for immune cells, 
it can also penetrate into epithelial cells in the mucosa via transcytosis. Thus, HIV can find a path 
through the cervicovaginal epithelium to the draining lymphatic via transport by lymphocytes and 
macrophages [17]. It has been shown that within 30-60 min of exposure, HIV can penetrate the 
cervicovaginal epithelium. The primary host for HIV infection are CD4+ T cells and Langerhans 
cells in the FGT. Langerhans cells also called dendritic cells can project their dendrites through 
the intercellular spaces of the vaginal epithelium and appear at the surface. Free virion can 
promptly bind to those dendrites and infect the cells [18]. During sexual intercourse, mechanical 
tearing of the cervicovaginal epithelium will increase access of HIV to its target cells, located in 
the basal epithelium underlying the stroma [18]. Infectious micro-organisms like herpes simplex 
virus or syphilis can create genital ulcers and inflammation leading to a gathering of HIV target 
cells and facilitate the entry of the virus through the epithelium and further to the lymph node. For 
example, the popular spermicide nonoxynol-9 (N9) has been used as a contraceptive and evaluated 
for its anti-viral properties against the herpes simplex virus and HIV. Unfortunately, N9 can induce 
an inflammatory response within the FGT attracting more immune cells increasing viral infection 
rates [19, 20]. 
The male genital tract is also a site of HIV entry. The mechanism of HIV uptake is similar 
to the FGT uptake. Removal of the foreskin during circumcision will significantly reduce HIV 
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target cells making the virus entry more difficult [21]. The surface of the penis is covered by a 
keratinized squamous epithelium that presents a great physical barrier for HIV entry, but the 
urethra is covered by a non-keratinized epithelium that shows the same weaknesses as the female 
cervicomucosa [22].  
 
 HIV entry into target cells.  
HIV target cells are essentially T cells, macrophages, and dendritic cells. HIV binds to its 
target cells using a portion of its envelope called gp120 (glyco-protein 120 kilodalton). When 
gp120 interacts with the cell surface receptor CD4, it will create new rearrangements of gp120 
loops that will allow the binding to a co-receptor, the chemokine receptor type 5 (CCR5), or to the 
chemokine receptor type 4 (CXCR4). Once gp120 binds to CD4, a portion of the virus envelop 
called gp41 will be inserted into the host membrane and create a fusion of the viral envelope and 
the plasma membrane of the cell [23].  
The Langerhans cells present in the sub-mucosa of the genital tract express the HIV 
receptor CD4, CCR5 and the C-type lectin receptor (plays a major role in cell adhesion and 
endocytosis) but not CXCR4. The internalization of the virus seems to be mostly through 
Langerhans cells where it is picked up by endocytosis and released to the other side of the 
epithelium to be picked up by other HIV target cells such as lymphocytes [24]. Langerhans cells 
can harbour the virus and transfer it to virus-free T-cells causing its activation [25]. CD4+T cells 
are found in the connective tissue lying beneath the epithelium known as lamina propria of the 
human vagina, and below the ectocervix and endocervix[26]. Most of them are memory T cells 
with a higher expression of the surface receptor CCR5 compared to the T cells found in the blood 
[27]. Hladik et al. found that within 2 hours after exposure to a virion, it can bind to the vaginal 
CD4+T cell and begin fusion [28]. This implies that ideal therapy against HIV-1 infection should 
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be effective within 1-2 hours of exposure from an infected donor. Active T-cells present at their 
surface a MHC II cell surface receptor called HLA-DR. An active T-cell presenting HLA-DR 
(HLD-DR+) receptor will have more affinity for HIV and increased susceptibility to viral infection. 
Studies have shown that even resting T-cells not presenting HLA-DR can fuse with HIV virion. 
Resting T cells (HLA-DR-) have also been reported to play an essential role in the early stages of 
HIV infection but are less susceptible to infection than HLA-DR+ cells [29]. Macrophages are a 
target of HIV in the initial infection but to a lesser extent than T cells and they are the primary 
target cells for HIV strains that use the co-receptor CCR5 and CXCR4 [30]. Monocyte-derived 
macrophages can internalize HIV by a process called macropinocytosis without the intervention 
of any specific cell surface receptor and store the virus for several days transmitting to T cells. The 
virion can also penetrate those monocytes using syndecans that are single transmembrane domain 
protein that enables the interaction with diverse ligands and HIV-1 gp120 protein [15].  Natural 
Killer (NK) cells and B lymphocytes have also been reported to transmit HIV to T cells in trans 
infection [31, 32].  
 
 Viral replication cycle.  
The envelope of the virus fuses with the plasma membrane of host cells, allowing all of its 
contents to be released in the cytoplasm of the host cell including its genome and proteins.  The 
genome of the virus is double-stranded RNA. Upon its transfer into the host cytoplasm, the genome 
is reverse transcribed into complementary DNA (cDNA) using reverse transcriptase (RT). The 
reversed transcription process will follow with the formation of the pre-integration complex (PIC) 
that will then be translocated into the nucleus. Inside the nucleus, the double-stranded DNA will 
merge with host genome using a viral protein called integrase. The machinery of the cell will carry 
on a regular cell division cycle with the genome of the virus integrated. The genome of the virus 
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can be silent in the host and multiply while remaining latent. To infect other cells, the provirus 
may be reactivated [33]. The viral genome is used to translate mRNA into viral proteins and 
genome. All the essential viral proteins will be fabricated using the host machinery. The virion 
components after being translated into proteins will be transported to the plasma membrane for the 
assembly. Once the entire parts are together, new virions will bud at the plasma membrane where 
they acquired their lipid envelope. Each newly created virus is composed of 3 major elements, 
which are the envelope, the viral proteins and the capsid that contains the viral genome [34].  
 
 Clinical sign of infection 
After HIV-1 infection, the virus will undergo the eclipse phase where it will not be 
detectable in the blood but multiply in immune cells. After 1 or 2 weeks, the virus will reach the 
lymph node and the gut-associated lymphoid tissue where there is an important number of CD4+ 
cells that will be infected, followed by mass production of virions [35]. The acute phase of HIV 
infection occurs when the viral markers are detectable in the blood, followed by massive death of 
CD4+ T lymphocytes due to apoptosis or pyroptosis [35]. The chronic phase is the last phase of 
HIV infection and last 10 to 20 years. During this phase, both immune cells and the virus replicate 
with a continuous depletion of the number of CD4+ T lymphocytes. The CD4+ T lymphocyte count 
is crucial to distinguish the severity of the disease. CD4+ T lymphocyte counts < 200 cells/l 
signifies a patient with severely compromised health increasing susceptibility to opportunistic 
infections like tuberculosis [36]. These opportunistic diseases are usually the cause of death for 





 Sex differences in HIV infection   
The UNAIDS reported that 52% of HIV-infected persons are women. In the same report, 
it is mentioned that the percentage of women aged 15-24 infected with HIV is twice that of young 
men.  After decades of research on AIDS, gender consideration is now a prime concern in an effort 
to stop the spread of the virus and the application of an effective treatment [13]. Women are more 
exposed to HIV than men for biological and socio-cultural reasons. The mucosal surface area of 
the FGT is greater than the male genital tract increasing exposure to HIV. Furthermore, semen 
remains longer within the FGT leading to a higher vulnerability. In developing countries, women 
are most of the time unable to negotiate condom usage, fearing a violent retort from their partners 
[37]. A young girl in the third world is more likely to marry an older HIV-positive man who is 
already in a polygamous relationship. The lack of education for girls in those countries makes them 
less aware of HIV infection and the different protection strategies [38, 39]. Well-educated women 
will be able to make their own choices regarding their sexual life. Protecting women from HIV 
will help decrease the number of HIV-born children via mother-to-child transmission. Most 
children are infected by their mothers during pregnancy, labour or breastfeeding. A promising 
study has shown that the rate of mother-to-child transmission has declined in developed countries 
because of the availability of drugs that can protect the child during the pregnancy [40]. 
Microbicide development for women is an encouraging strategy that will significantly impact the 








 Current state of microbicide development  
 HIV prevention strategies 
1.1.8.1.1. An overview 
Efforts in developing an effective vaccine for HIV-1 are challenging as HIV strains are 
highly variable with the capability of undergoing recombination with high error rates during the 
reverse transcription process [41]. These highly variable conserved regions are usually 
thermostable and concealed with heavy glycosylation coverage [42], leading to significant 
difficulties for anti-HIV antibodies to recognize and neutralize the virus efficiently. Therefore, in 
the absence of an effective vaccine against HIV, consistent usage of condoms is still the 
cornerstone of prevention. Due to the lack of condom accessibility in some developing countries 
and the unwillingness of condom usage by sexual partners due to socio-cultural factors, other 
alternative interventions have been studied to be employed as additional prevention strategies such 
as male circumcision and the use of antiretroviral drugs for the treatment of HIV infection [43]. 
These proposed biomedical prophylactic interventions include postexposure prophylaxis (PEP), 
preexposure prophylaxis (PrEP) [44], and more recently, the induction of T-cell immune 
quiescence (IQ) at the FGT [45].  
 
1.1.8.1.2. Preexposure and postexposure prophylaxis 
Thanks to advancements in antiretroviral therapy, HIV is no longer considered a terminal 
disease but a manageable condition that can be controlled under a long-term intervention using 
antiretroviral drugs. PrEP and PEP were proposed as such strategies that utilize antiretroviral drugs 
to prophylactically intervene in HIV infection before and after an incident of HIV viral exposure.  
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In a case-control study where individuals were given the prophylactic zidovudine post-viral 
exposure, there was an 81% reduction in infection [46]. However, due to ethical and logistical 
concerns, further initiation of a randomized controlled clinical trial aiming to systemically evaluate 
PEP regimens is considered not feasible. PrEP, on the other hand, is currently the most promising 
HIV prevention strategy which involves the administration of antiretroviral drugs on a daily basis 
to HIV-negative persons prior to potential exposure to the virus. The rationale behind PrEP is to 
inhibit viral replication immediately after viral exposure, resulting in the abolishment of the 
infection (Table 1.1). Two promising nucleoside/nucleotide reverse transcriptase inhibitors, 
tenofovir (TFV) and emtricitabine (FTC), showed high effectiveness and toleration in HIV 
treatment with evidential HIV prevention effects in clinical studies. As a result, this combination 
treatment is now sold under the brand name Truvada® and approved for PrEP against HIV. 
However, it should be kept in mind that the most important prerequisite to maintain PrEP efficacy 
is to achieve high levels of drug adherence as shown in failed clinical trials such as FEM-PrEP 
[47] and VOICE [48] trials, where both trials had poor patient adherence of <40% and <30%, 
respectively. Thus, to improve drug concentrations at the FGT and increase patient adherence, 









Table 1.1 Milestone PrEP clinical trials 
 
Abbreviations: FTC, emtricitabine; MSM, men who have sex with men; TDF, tenofovir disoproxil fumarate; TFV: tenofovir  
Clinical Trial Study 
Population 
Mode of HIV 
Infection 
Regimen Estimated Efficacy of 
HIV Prevention (%) 
Ref 




Truvada®; once oral daily 63% [49] 




TDF (200 mg) only; TDF (300 mg) + 
FTC (200 mg); once oral daily 
67% in TDF only arm; 
75% in TDF/FTC arm 
[50] 
iPrEx trial MSM and 
transgender 
women 
Rectal Truvada®; once oral daily 44% [51] 
PROUD trial MSM Rectal TDF (245 mg) + FTC (200 mg); once 
oral daily 
86% [52] 




TFV (300 mg); once oral daily 49% [53] 
FEM-PrEP trial Women Vaginal or 
penile 
Truvada®; once oral daily stopped early due to 




1.1.8.1.3. Induction of T Cell immune quiescence at the FGT as a 
preventative strategy 
Elevated immune activation systemically and locally at the FGT [54] is one of the 
hallmarks during HIV infection. The resulting systemic and local mucosal inflammation can 
significantly contribute to the progression of HIV transmission, which is usually represented by 
increased immune cell activation (activated HIV-target cells such as T cells, dendritic cells, etc.) 
coupled with elevated production of pro-inflammatory mediators [54]. Activated immune cells are 
necessary for HIV replication and are more prone to HIV infection compared to their resting 
counterparts [45]. However, a lower base level of immune activation was observed in some HIV-
exposed seronegative (HESN) individuals who are naturally resistant to HIV-1 infection [45]. T 
cell IQ status was observed in these HESN individuals [45] which showed lower expression of T 
cells activation markers such as CD69, CD38, HLA-DR, Ki67, and CCR5. At the same time, it is 
found that these individuals with high levels of quiescent T cells are still able to initiate normal 
antigenic and mitogenic responses [55]. Therefore, if T cell IQ can be pharmacologically induced 
at local HIV transmission sites such as the FGT, it may inhibit local HIV infection due to decreased 
availability of activated T cells leading to less productive transmission and replication of HIV. 
Eventually, the clearance of acutely infected cells may be achieved through local HIV-specific 
cytotoxic T cells with the assistance of regulatory T cells or other innate mechanisms [45], or by 
antiretroviral drug intervention. Our group recently developed a polyurethane vaginal implant 
delivering the immunomodulatory drug HCQ within the vaginal tract of rabbits. Our results 
showed that the implant was capable of attenuating pro-inflammatory mediator production and 
decrease gene expression of CCR5 and CD69 in isolated vaginal mucosal T cells even after 
challenge with the surfactant N9 [56]. 
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1.1.8.1.4. Passive immunization 
Currently, there is a lack of an effective vaccine against HIV, but passive immunization 
approaches using broadly neutralizing antibodies (bNAbs) against HIV administered either 
systemically or locally at the FGT to prevent HIV-1 infection in the vaginal mucosa has 
demonstrated promise in preclinical studies and early-stage clinical trials [57]. A phase 1 clinical 
trial utilizing a vaginal microbicide containing a combination of bNAbs 2F5, 2G12, and 4E10 
formulated in a gel was recently completed, showing that 12-day vaginal delivery of 50 mg of each 
antibody can be achieved safely in the female participants [57]. Another phase 1 trial examined 
the safety and pharmacokinetics of intravenously or subcutaneously administered bNAb VRC01 
over a 28-day period, revealing that VRC01 retained neutralizing activity in serum without anti-
VRC01 antibody responses [58]. The efficacy of systemic delivery of VRC01 to prevent HIV 
infection is currently on-going with healthy women that are considered at high risk of HIV 
acquisition [59]. Kang et al. are currently evaluating the safety of a genetically modified and killed 
whole-HIV-1 in phase 1 clinical trials. The SAV001 vaccine study was safe for all participants 
and the antibodies produced in the plasma recognized HIV-1 envelope protein on the surface of 
infected cells. The antibodies exhibited broad neutralizing activity inhibiting tier I and II of HIV-









 Microbicide dosage forms 
1.1.8.2.1. Vaginal and rectal formulations  
Microbicides are topical therapies developed to prevent HIV and other sexually transmitted 
infections during intercourse (Figure 1.1).  Microbicides applied vaginally or rectally are intended 
to prevent HIV infection at the site of transmission by either preventing viral replication or 
inhibiting its entry into immune cells. Some possible mechanisms of action of microbicides are to 
hinder HIV entry into its target cells, to boost the immune system’s fight against the viral infection, 


















Figure 1.1: Potential activity of microbicides to prevent HIV infection.  [62] A free virion at 
the mucosal surface can rapidly cross the mucosal epithelial barrier to infect its target cells. 
Microbicides can act at different stages of viral infection. Microbicides can hinder virus 
movement in the mucus prior to cell infection. Once inside the target cells, the delivery of some 
inhibitors like nucleoside and non-nucleoside reverse transcriptase inhibitors can prevent the 
virus multiplication.   
16 
 
1.1.8.2.2. Vaginal films and gels  
Vaginal films have been formulated to deliver therapeutics in the FGT. Vaginal films are 
solid dosage forms that rapidly dissolve in contact with vaginal fluid, are mainly composed of 
polymers, plasticizers and the active therapeutic agent. The films are designed to prevent or 
decrease HIV infection. Two main manufacturing processes used for the fabrication of vaginal 
films include solvent casting and hot melt extrusion methods [61]. The latter is used only if the 
drug is stable at high temperatures. An example of an approved vaginal film is the contraceptive 
N9 film from Apothecus Pharmaceutical Corporation (VCF® Vaginal Contraceptive film). 
Numerous film formulations have been developed during the past several years as potential 
microbicides against HIV infection [63]. In a recent phase 1 clinical trial, dapivirine vaginal film 
was evaluated for patient compliance, safety, and drug distribution in healthy women. In this study, 
HIV-negative women were randomly subjected daily for seven days to either a 
hydroxyethylcellulose (HEC) placebo gel, 0.05% dapivirine gel, placebo film, or film containing 
1.25 mg of dapivirine [64]. Researchers found that the plasma concentration of dapivirine was four 
log10 lower than the concentration in cervical and vaginal tissue. The gel users had a higher content 
of the drug in the tissue but both formulations significantly reduced HIV infection ex vivo. 
Participants in the study preferred the film formulation since it is not linked to any messiness, but 
found the gel was easier to apply than the film. TFV film formulations have also been evaluated 
in a clinical setting in HESN women [65]. This study investigated a single-dose vaginal film or 
gel application and found that the film formulation gave a higher concentration of the drug in the 
plasma and vaginal tissues during the first days compared to the gel formulation, but after day 3-
7, both groups demonstrated similar concentrations [65]. Unfortunately, ex vivo HIV challenge 
studies using the film or the gel formulation failed to protect against infection. The authors claim 
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that the failure to protect against infection is due to the decrease in drug concentration over time 
after a single dose regimen [65]. These studies suggest that multiple dosing with film may be 
necessary to maintain protective concentrations of drug before HIV challenge. 
 
1.1.8.2.3. Intravaginal ring 
IVRs, initially introduced for contraception and hormone replacement therapy, received 
much attention recently as novel anti-HIV microbicides to provide prolonged and controlled drug 
delivery [66]. IVRs are commonly fabricated using high-temperature methods such as hot-melt 
extrusion or hot injection molding. Thanks to the flexible choice of thermoset or thermoplastic 
polymers ranging from silicone, ethylene-vinyl acetate, to polyurethane [66], different 
pharmaceutical agents can be incorporated into IVRs in a large quantity to achieve cumulative 
drug release in a sustainable and predictable manner [66]. There are two major categories of 
conventional IVRs involving matrix-based and reservoir-based IVRs. In a matrix-based IVR 
system, the pharmaceutical active ingredients (APIs) are dispersed uniformly within the polymeric 
matrix of the IVR during the fabrication. The drug release is correlated with both drug loading and 
the surface area of the device and demonstrates a diffusion-permeation release mechanism [66]. In 
a typical reservoir-based IVR system, however, the APIs are usually formulated into a semi-solid 
dosage form with release rate-controlling excipients and then loaded into a semi-permeable hollow 
tubing, in which the drug release rate is determined by both the surface area of the device and the 
physico-chemical properties of the polymers used to fabricate the semi-permeable tubing and 
excipients used to form the drug-excipient core [67]. For example, our group developed a 
polyurethane IVR system capable of sustained delivery of HCQ over a two-week period that did 
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not present any significant cytotoxicity in vitro towards vaginal epithelial cells and vaginal flora 
[68, 69].  
Currently, there is increased interest in multi-purpose microbicide development. Several 
innovative designs of IVRs targeting different pathogenesis of sexually transmitted diseases or 
targeting different types of sexually transmitted infections or possessing extra protection from 
unwanted pregnancy have been developed. For example, a pod-insertion silicone-based IVR was 
described to deliver five drugs simultaneously in a sheep model [70]. Each IVR carried 32 mg of 
TFV, nevirapine, saquinavir, and estradiol along with 20 mg of etonogestrel. The constant release 
of these drugs into sheep FGT was achieved over 28 days. In addition, IVRs can also be developed 
to allow the long-term delivery of heat-sensitive macromolecules, offering an attractive platform 
to develop vaginal mucosal vaccines for inducing vaginal mucosal immunity against HIV or direct 
delivery of HIV neutralization antibodies against HIV. McKay et al. recently described a novel 
antigen-releasing IVR capable of releasing human HIV-1 recombinant protein CN54gp140 and its 
adjuvant R848, yielding a 30-fold increase in mucosal IgA response and higher presence of 
antigen-specific B cells in the genital draining lymph nodes of the sheep model [71]. 
IVRs also offer improved user adherence in comparison to other delivery systems as it requires 
minimal action on the part of the user to achieve product adherence since daily, intermittent, or 
coitally-associated application of an active ingredient is not required [66]. An on-demand release 
of API IVR system was developed by Kim et al., with an insertion-type intravaginal ring with 
reversible pH-responsive polyurethane membranes to control drug release [72]. Very small pore 
sizes are observed in the membranes at vaginal pH, but larger pore size begin to appear at high 




1.1.8.2.4. Rectal microbicides  
Unlike vaginal microbicides that mostly protect women against HIV infection during 
sexual intercourse, rectal microbicides must be designed to protect both in the case of men who 
have sex with men (MSM) or rectal heterosexual intercourse. People engaged in receptive anal 
intercourse mostly do not use condoms compared to those engaged in vaginal intercourse [73]. 
Microbicides for rectal delivery are usually formulated as a gel, fluid (enema), or suppository. An 
excellent review by McGowan et al. summarized the different types of rectal microbicides and the 
drugs used in the formulations [73]. In this review, we will focus on current formulations that have 
already been completed or currently in clinical phase of testing. In terms of rectal microbicides, 
not many have made it to clinical trials. TFV, dapivirine, and UC-781 are the drugs that have been 
most evaluated. A clinical trial published in 2011 assessing the acceptability, safety and ex vivo 
efficacy of the reverse-transcriptase UC-781 showed some promising results [74]. Although this 
study did demonstrate that the gel formulation with UC-781 was safe, with high adherence and 
was effective in preventing HIV infection ex vivo, to the best of our knowledge we could not find 
any subsequent clinical trials further evaluating this product probably because of its extremely 
poor water solubility that makes it difficult in formulation development [75]. TFV has been 
extensively evaluated in clinical trials for the formulation of rectal microbicides. A phase 2 
randomized clinical trial compared daily oral emtricitabine/tenofovir disoproxil fumarate, daily 
use of reduced-glycerin 1% tenofovir rectal gel and reduced-glycerin 1% TFV rectal gel before 
and after receptive anal intercourse [76]. After the 8-week study, there was more than 80% 
adherence for patients in the rectal application before and after rectal intercourse group compared 
to the daily oral formulation group (41%) and the daily rectal gel application group (29%). It is 
not a surprise that the daily gel application group exhibited low adherence since it is very 
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inconvenient to apply the rectal gel daily when there is no sexual intercourse. Naturally, the 
formulation for the gel application before and after rectal intercourse must have sufficient active 
compound in order to rapidly reach therapeutic levels when used during those two times. A similar 
phase 2 trial published by Cranston et al. corroborated the previous findings [77]. 
 
1.1.8.2.5. Nanotechnology-based systems 
Nanomedicine is a fast-emerging field during the past several decades. NPs have been 
massively used in health research for the prevention, treatment, and diagnosis of different diseases. 
NP formulations are typically categorized as viral-based or non-viral NPs.  Viral NPs mainly use 
viral components for gene delivery. This method can achieve high transfection efficiency but can 
result in severe adverse reactions [78], and as a result, will not be focused on in this review. The 
majority of NPs evaluated for HIV prevention or treatment have been non-viral based and are 
composed of lipids and/or polymers. When developed as a microbicide, NPs play essential roles 
in drug solubility, protection of the drug formulation, enhancing targeted drug delivery, 
modification of drug safety and toxicity, and can influence pharmacokinetics and 
pharmacodynamics of certain drugs [79].  
One of the well-known nano-systems used as a microbicide and has entered phase 1 clinical 
trial is the SPL 7013 dendrimer gel Vivagel® [80]. This dendrimer is designed to interact with 
gp120 to inhibit direct entry of HIV and has demonstrated virucidal activity on certain strains of 
HIV. In a phase 1 trial, Vivagel® when used by women, was safe and had high tolerability [80]. 
The likelihood of this microbicide to work depends highly on its adherence, but unfortunately, in 
the same study, participants raised the same problems known with gel formulations mainly the 
leakiness and the hindrance with sexual intercourse in some cases.  NPs have been used in gene 
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therapy to hinder HIV infection or viral replication via the delivery of nucleic acids [79]  and for 
the delivery of small molecule drugs such as saquinavir [44].  
Polymeric NPs present numerous advantages such as biodegradability and good 
biocompatibility, as well as mucoadhesive properties, which, for example, allow the NPs to remain 
longer in the FGT providing sustained drug release. In a study by Lakshmi et al., the team 
developed a combination platform against HIV [81]. In this study, lactoferrin, which has direct 
anti-HIV properties, was used to encapsulate efavirenz and curcumin. These NPs had a size of 40-
70nm and were able to encapsulate up to 63% of curcumin and 61% of efavirenz. Furthermore, 
improved tissue and plasma concentrations were reported with the NP group compared to free 
drug[81]. In addition, poly(lactic-co-glycolic acid) (PLGA) conjugated to polyethylene glycol 
carrying siRNA against SNAP23, a gene involved in HIV escape from immune cells, has also been 
evaluated for its potential as a vaginal microbicide [82]. In these studies, the NPs were attached to 
anti-HLA-DR antibody for active targeting to dendritic cells. The mucus at the mucosal surface of 
the FGT can hinder viral movement but can also slow down NPs crossing the mucosal barrier into 
the submucosa. Maisel et al. designed polystyrene NPs densely coated with low-molecular-weight 
poly-ethylene-glycol (PEG) to prevent interaction with the mucus which enhanced NP penetration 
[83]. This NP formulation was capable of rapidly crossing the mucosal layer in a mouse model 
[83]. 
Lipids are also useful materials for developing NP-based microbicides.  For example, a 
commercially available liposomal formulation called novasome used for the encapsulation of 2-
RANTES, a synthetic homolog of RANTE, demonstrated promise in a non-human primate SHIV 
challenge model [84]. In the study, 2-RANTES was used to block the CCR5 co-receptor to prevent 
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SHIV infection. Solid lipid NPs functionalized with polylysine-heparin have also been developed 
by Alukda et al. to encapsulate tenofovir as a drug model [85]. 
Hybrid NPs comprised of polymers and lipids have also been investigated for anti-HIV 
applications. For example, Boyapalle et al. evaluated a NP formulation mixing chitosan and lipids 
to form a chimera called chlipid nanocomplexes [86]. The nanocomplex was used to encapsulate 
and deliver siRNA for anti-HIV/SHIV evaluation. The nanocomplex was delivered in a cream 
formulation intravaginally to non-human primates and demonstrated a significant reduction in 
SHIV viral titer [86]. 
 
1.1.8.2.6. Stimuli-responsive formulations 
Stimuli-sensitive materials for applications in drug delivery are a promising approach for 
achieving on-demand drug release. Stimuli-responsive polymers are able to deliver their active 
compounds at the appropriate time and site of action in response to specific triggers [87]. Different 
stimuli can be considered in the design of drug delivery systems such as temperature, pH, light, 
electric and magnetic fields, or enzymatic [87]. The FGT has a normal pH around 3.8-4.5 [88] 
which is a property that can be utilized to design drug delivery systems that respond to changes in 
the acidity of the vaginal area. In fact, during sexual intercourse, the presence of seminal fluid (pH 
7-8.5) [88] can increase the pH of the FGT up to around neutral for 6 to 8 hours [89]. In a study 
published by Mahalingam et al., the authors developed a synthetic mucin-like polymer that will 
crosslink upon increases in pH to impede the movement of free HIV [90]. This pH-responsive 
polymer was made of phenylboronic acid and salicylhydroxamic acid copolymerized with 2-
hydroxypropyl methyacrylamide. At vaginal pH, the polymer is partially crosslinked and can slow 
down the viral movement with a relaxation time of 0.9 s and elastic modulus of 11 Pa. In the 
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presence of basic semen, the crosslinking becomes denser with a relaxation time of 60 s and an 
elastic modulus of 1800 Pa. Movement of HIV was reduced with a diffusion coefficient of 1.60 x 
10-4 m2/s. 
Besides using change in pH in the vaginal tract to trigger drug delivery, Clark et al. 
evaluated a vaginal delivery system using enzymes as a release trigger [91]. In this study, microgel 
particles containing the HIV-1 entry inhibitor sodium poly(styrene-4-sulfonate) were fabricated 
with a crosslinker containing a peptide substrate for serine proteases present in seminal fluid called 
prostate-specific antigen. Upon ejaculation in the FGT, the enzymes contained in the ejaculate 
degrades the crosslinkers and releases the therapeutic compound. The study revealed that after 30 
min of exposure, the concentration released (10 g/mL) is equivalent to the published IC90 for the 
drug. Recently, a research article published by Coulibaly et al. utilized HIV-1 gp120 fragment’s 
ability to interact with the drug carrier to trigger drug release [92]. In this study, TFV was 
encapsulated in a mannose responsive particle using calcium carbonate, concanavalin A and 
glycogen. This study was intended to address the unnecessary drug release while the virus is not 
present. Stimuli-responsive drug delivery systems are also known as “smart delivery systems” and 
may help to tailor drug delivery in a specific situation to prevent unnecessary drug release as a 
strategy to reduce adverse effects when the drug is not needed. 
 
1.1.8.2.7. Electrospun fibers 
Electrospinning has been around for a while, but its usage in microbicide development is 
still at an early stage. Ball et al. defined the electrospinning process as “the transformation of 
polymer melts or solution into collections of fine fibrous strands of material using a strong electric 
field. The resulting materials are typically opaque, soft, foldable sheets of polymer capable of 
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taking nearly any shape” [93]. There is an excellent review covering the different electrospinning 
techniques and materials used in the electrospinning process [93]. For example, In a study by 
Huang et al., TDF (Tenofovir Disoproxil Fumarate ) (Viread), a pro-drug of TFV, and Etravirine 
(TMC 125) were mixed with cellulose acetate phthalate and electrospun into fibers to protect the 
drugs from releasing in normal vaginal pH but released in the presence of human semen  [94]. The 
fibers did not present any cytotoxicity towards vaginal epithelial and lactobacilli cells in vitro, 
appeared safe in a mouse model and prevented HIV infection in vitro [94]. Recently, Tyo et al., 
published on the pH-responsive delivery of the broad-spectrum antiviral protein griffithisin from 
electrospun fibers [95]. Electrospun fibers are a compelling platform that should be further 
explored as potential microbicide formulations. 
 
1.1.8.2.8. Modified microbiota for microbicide drug delivery  
The FGT is dominated by bacteria specifically those from the lactobacillus family, playing 
an important role in protecting against external infections. Studies have shown that lactobacilli 
present in the FGT were able to protect against HIV infection by the acidification of the medium, 
and also the nature of the lactic acid produced was able to inhibit the virus even if the pH was 
increased to 6.9 [96]. They also found the bacteria themselves have a direct virucidal effect [96]. 
Unfortunately, this natural defense is not sufficient to completely protect against HIV infection. 
Since bacteria can be engineered to produce specific proteins of interest, scientists have attempted 
to modify the natural flora to produce anti-HIV moieties capable of preventing HIV infection 
(Table 1.2) [97]. Lagenaur et al. published a study where they prepared a stable lyophilized tablet 
containing Lactobacillus jensenii engineered to express the HIV-1 entry inhibitor cyanovirin-N 
(mCV) [98]. Five tablets were inserted into the FGT (one tablet per day over five days) of 
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macaques. The tablets were completely disintegrated in 2 mins and colonization of the FGT by the 
modified bacteria was 66% after 14 days and 83% after 21 days. Western blot was used to confirm 
the presence of mCV-N. Although this is a promising platform to fight against HIV infection, this 
technique involving the use of genetically modified organisms will require additional studies to be 
conducted to demonstrate long-term safety and stability of the engineered bacteria before moving 
































Table 1.2: Engineered microbiota as microbicides to prevent HIV infection 
 
Engineered bacteria  Encoded inhibitors  Target  Ref 





CD4 D1 D2 Entry inhibitor 
(gp120) 
[100] 
Lactobacillus jensenii C1C5 CCL5 Entry inhibitor 
(CCR5) 
[101] 
Lactobacillus gasseri CCL5; CCL3 Entry inhibitor 
(CCR5) 
[102] 


















1.1.8.2.9. Challenges in microbicide drug delivery  
Microbicide development was intended to be a breakthrough in the combat against HIV 
infection particularly in the absence of an effective vaccine. The ideal formulation should be 
reasonably easy to use, comfortable to increase patient adherence, must be capable of delivering 
sufficient drug uniformly throughout the FGT and rectum, and preferentially remain at the site for 
prolonged periods of time to provide complete and effective protection against HIV [103]. Table 
1.3 presents some novel HIV prevention strategies evaluated in pre-clinical or in clinicals trials.  
The majority of microbicide formulations are considered “single-use”, meaning that it is to be 
applied immediately before and after sexual intercourse. This can pose as a major inconvenience 
to patients resulting in a significant decrease in adherence. A potential solution to address some of 
these challenges is to formulate the microbicide into an IVR, which theoretically is not considered 
messy, does not require the patient to apply at the time of sexual intercourse, and can provide 
prolonged protection e.g. >21 days. Drug transporters and metabolizing enzymes may also play an 
important role in the therapeutic efficacy of the delivered drug. Zhou et al., examined the 
expression profile of 22 transporters and 19 metabolizing enzymes found in the FGT [104]. Certain 
antiretroviral drugs were shown to be affected by transporters such P-gp, BCRP, OCT2, and ENT1 
and were more highly expressed in the lower genital tract compared to the liver. As for the 
metabolic enzymes, CYP isoforms were absent in the FGT while UGT1A1 was highly expressed 
[104]. Understanding all the factors around drug metabolism and transport will significantly help 
in the design of more effective microbicides. 
Recently, a series of research has investigated the potential impact of the microbiome on 
the efficacy of microbicides evaluated in clinical trials. In the study published by Klatt et al., it 
was shown that women with impaired microbiota with a high content of Gardnerella vaginalis 
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experienced reduced effectiveness when they received 1% TFV gel [105]. In a previous study, 
Gardnerella vaginalis which causes bacterial vaginosis in the absence of lactobacilli, was found 
to exacerbate the production of inflammatory cytokines, which may facilitate HIV infection [106]. 
In an in vitro study, the authors found that Gardnerella vaginalis rapidly degraded TFV by 50.6% 
compared to Lactobacillus iners, Lactobacillus crispatus, and control without any bacterium 
[105]. This study highlighted the importance of vaginal microbiota while delivering TFV and 




Table 1.3. Other Novel HIV prevention strategies evaluated pre-clinically or in clinical trials 













Efficacy of HIV 
Prevention (%) or 
Other Notes  
On-demand 
PrEP[107] 
Phase 3 clinical trial MSM Rectal Oral tablet two tablets 2-24 
hr prior to sex 
followed by one 
tablet each at 24 




mg) + FTC 
(200 mg) 
86% 
PrEP derived[108] Phase 1clinical trial Women Vaginal or 
penile 






PrEP derived[109] Phase 3 clinical trial Women Vaginal or 
penile 
IVR 4 weeks DPV (25 
mg) 
Overall 27%; 37% 
for high adherence 
group 
IQ[54] Pilot trial study Women Vaginal or 
penile 
Oral tablet daily 
administration 
HCQ (200 
mg) or ASA 
(81 mg) 
Reduced HIV target 
cells at FGT; 
decreased CCR5 
expression on 
mucosal CD4+ T 
cells 
IQ[56] Pre-clinical animal 
study 









protein expression of 
HLA-DR and 
decreased gene 
expression of CCR5 
and CD69 on 





Phase 1 clinical trial Women Vaginal or 
penile 




4E10, 50 mg 
each 
Safety demonstrated 
over test period 
Passive 
Immunization[111] 





Once or twice IV 
or SC 
administration of 
VRC01 in a dose 
escalation plan 
over 28 days  
bNAbs 
VRC01 




Abbreviations: ASA, acetylsalicylic acid; bNAbs, broadly neutralizing antibodies; DPV, dapivirine; FTC, emtricitabine; HCQ, 
hydroxychloroquine; IQ, immune quiescence; IV, intravenous; IVR, intravaginal ring; MSM, men who have sex with men; SC, subcutaneous; 




 Intravaginal ring design 
An IVR is a torus-shaped polymer that can deform when pinched into a figure-eight shape. 
Three principal polymers are used in microbicides notably the thermoset silicones, the 
thermoplastic poly (ethylene-co-vinyl acetate) EVA and thermoplastic polyurethanes [112]. From 
those polymers, four types of IVRs are usually used to deliver active compounds within the vaginal 
lumen. First, there are matrix-type IVRs where the drug is distributed homogenously throughout 
the ring. A second type is the reservoir-type, which is similar to hollow tubing where the drug will 
be loaded into the lumen, and the two ends will be sealed together to form a ring shape [113]. The 
third type is an insert-type IVR. Small drug cores can be fabricated separately and coated with a 
rate-controlling membrane before inserted into the IVR. The fourth type is the segmented IVR 
allowing the combination of multiple segments from different polymers containing different drugs 
that are joined together to form the torus shape [114]. The matrix-type IVR will usually 
demonstrate a first-order release which means that the amount of drug released is proportional to 
the concentration at the present moment, e.g., more drug present in the ring will result in faster 
drug release. However, with the reservoir-type IVR, zero-order kinetics can be achieved, providing 
a constant rate of release. It is important to take into consideration the nature of the drug and the 
chosen polymer for controlled drug release, e.g., the solubility of the drug in the elastomer, the 
diffusion coefficient of the drug in the elastomer and the solubility of the drug in vaginal fluid. 
The volume of vaginal fluid produced and the partition coefficient of the drug between the IVR 
and the vaginal tissue are also essential [112, 114].  
For an IVR to be able to release a drug for an extended period, it depends on its ability to 
stay in place within the vaginal lumen. Therefore, a typical IVR must not be able to deform easily 
within the vaginal tract or fall out. This can happen during daily activities such as coughing or 
running. On the other hand, if the ring is too rigid, it will cause irritation or damage to the vaginal 
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tissue resulting in severe inflammation [115]. Every woman is different including the size of their 
FGT. As a result, an IVR must be designed taking into consideration an optimum size that will 
allow the ring to fit into most vaginal tracts without causing any damage. Studies have shown that 
IVRs designed with an outer diameter of around 55 mm and with a cross-sectional diameter 
between 5 and 6mm are safe for humans [116].  
 
 Discreet use of IVR for women and adherence  
In the third world, some women have difficulties negotiating the use of condoms with their 
partners. Sex workers are not always able to negotiate safer sex with their clients in fear of 
retaliation or reduced incomes. Microbicides will empower women to protect themselves against 
an infected partner without their consent. Women can place the IVR discreetly in the genital tract 
without the knowledge of their partner. Many of the previous intravaginal devices require a 
healthcare professional for insertion/placements e.g. intrauterine devices. IVRs can be 
inserted/removed easily and rapidly by women without professional help. Since the ring can be 
inserted for a long period of time, this will reduce the burden associated with daily application, 
which will improve patient adherence. 
It is important to understand the difference between patient acceptability and patient 
adherence. Acceptability is defined as the extent to which a product is desirable to the target user 
population, and adherence is the extent to which users obey specified dosing instructions [117]. A 
study conducted by Novak & al. showed that 66% of participants chose oral contraceptives instead 
of the ring at the beginning, but after using it for a while, 81% were happy with the ring [118]. 
85% of the women in the study never or rarely noticed the presence of the ring during intercourse, 
and 74% of their partners hardly noticed the presence of the ring. 94% of women's partners had 
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little or no concern about the use of the ring. The acceptability of the ring was high because of the 
simplicity in its usage and improved conveniene (the ring can be used for a prolonged period)  
[118].  
 
 Effect of intravaginal ring on vaginal mucosa and biofilm formation  
An IVR is a foreign device to the human body fabricated from medical grade polyurethane 
to improve biocompatibility and reduce the risk of inflammation. The vaginal environment is 
complex and involves a lot of microorganisms. An alteration of the vaginal flora can severely 
decrease the number of lactic acid-producing bacteria naturally present in the FGT and keep the 
acidic pH. A decrease of those bacteria will follow an increase of the vaginal pH >4.5 and lead to 
the installation of other microorganism pathogens [119]. The presence of foreign pathogens in the 
genital tract can lead to an inflammatory response called vaginitis. The most common vaginitis is 
bacterial vaginosis caused by Gardnerella vaginalis [120]. Numerous studies have shown that 
bacterial vaginosis may ease HIV infection [121-123]. The impact of the IVR on the vaginal 
microbiota must be carefully monitored so that it does not create unnecessary inflammation and 
enhance HIV infection.  
On the other hand, the vaginal flora can also have an impact on the ring. It is possible for 
an IVR that stays longer than three weeks in the vaginal tract to develop biofilm formation on the 
surface of the ring.  The biofilm growth can affect the release rate of the active compound from 
the ring. Not many studies have been done to evaluate this, but Manjula et al. reported the presence 
of a layer of dead epithelial cells on the surface of the ring worn by six female pig-tailed macaques 
for 28 days. They found the presence of two different phenotypes of bacterial biofilm on the ring. 
The phenotype I formed a bacterial mat with a thickness of approximately 5m. The phenotype II, 
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less common than the first one, created a mat of 40 m [124].  Unfortunately, this study did not 
focus on the effect of those biofilms on drug release. More studies must be done regarding the 
impact of the IVR on the microbiome and the effect of the microbiome on the IVR in long-term 
use. 
  
 Gene therapy as a potential strategy for preventing HIV infection 
Gene therapy offers continuous interference with viral replication. It can be a good 
alternative if there is no chemotherapy to act on a specific target or to reduce drug resistance. There 
are different approaches for gene therapy to prevent HIV infection. One of the main approaches is 
using RNA-based agents as prevention strategy. For example,  RNA interference (RNAi) is a 
process whereby double-stranded RNA (dsRNA) can induce post-transcriptional gene silencing in 
cells [125]. RNAi uses small interfering RNA (siRNA) or short hairpin RNA (shRNA) to 
knockdown a specific gene expression to prevent HIV replication. Gu et al. demonstrated siRNA 
can be used to silence the expression of  synaptosome-associated 23-KDa  as a strategy to prevent 
HIV virion to escape the host cell [82]. Another example of RNA-based gene therapy molecule is 
RNA aptamers. They have a high affinity to bind to a specific target. For example,  Ramalingam 
et al. raised HIV-1 Gag protein RNA aptamers to prevent HIV replication [126]. Duclair et al. used 
RNA aptamers to inhibit HIV-1 protease activity and also prevent viral replication [127]. 
Another gene therapy strategy to genetically modified host cells to produce anti-viral particles in 
effort to prevent HIV infection. For example, Falkenhagen et al, modified CD4+ using plasmid to 






In the process of RNAi, the RNase III Dicer processes dsRNA of 21-25 nucleotides long 
called siRNA or micro-RNA (miRNA). siRNA is incorporated into the RNAi-induced silencing 
complex (RISC) where it promotes the degradation of the target mRNA in a sequence-specific 
manner by Argonaute 2 (Ago) or hindering its translation into proteins in the cytoplasm [129]. 
After the dicer has processed the dsRNA, the resultant siRNA is double-stranded and contains 
three overhangs of two nucleotides. If the synthetic siRNA is directly injected into the cell, it can 
bypass the requirement for dsRNA processing by Dicer and immediately be incorporated into the 
RISC complex. The double-strand siRNA is unwound by a helicase in RISC. The untwisted anti-
sense strand is matched to messenger RNA (mRNA) that carries a high degree of sequence 
complementarity (the gene of interest). The mRNA will then be cleaved. The cleavage of the 
mRNA is directed by an Ago protein, which is an important part of the RNAi machinery associated 
with siRNA.  The RNAi processing gives two small interfering RNAs that are siRNA and miRNA. 
Dicer enzymes can cleave long dsRNA and stem-loop precursors into siRNA or miRNA in an 
ATP-dependent manner, respectively. The Dicer does cleave not only the RNAi but also helps the 
siRNA-RISC loading. It has been reported as well that siRNA with 3' overhang in the antisense 
operate better than siRNA with asymmetric sense strand overhang [130, 131].  
 
 siRNA-directed inhibition of HIV-1 infection 
siRNAs are used to target many stages of the HIV-1 infection and replication cycle 
including the knockdown of host cell membrane receptors such as CD4, CXCR4, and CCR5. For 
example, Novina et al. showed a decrease in HIV entry by silencing the expression of CD4 
receptor. Transfection with CD4-siRNA reduced CD4 expression by 75%, which also resulted in 
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a four-fold decrease in HIV infection [132]. Using gene therapy against HIV has many advantages. 
For example, in the absence of drugs to act on a specific target, siRNA can be individually 
customized to target the gene of interest. Systemic toxicity and off-target effects associated with a 
conventional drug can be reduced as well as decreases in the development of drug resistance by 
microorganisms.  
As discussed before, CCR5 co-receptor is the dominant receptor involved in HIV-1 entry 
into target cells along with the CD4 receptor. A report stated that people lacking CCR5 genes are 
resistant to HIV-1 infection [23]. In this project, we will be using siRNA to knockdown the 




Figure 1.2: Schematic of the CCR5 expression inhibition by siRNA 
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 siRNA delivery vehicle in the vaginal mucosa  
Naked siRNA has a net negative charge and is hydrophilic, preventing it from crossing the 
plasma membrane and entering cells. Naked siRNA can trigger an immune response and become 
degraded before it reaches its target. Enzymatic degradation by RNase is a significant risk for 
naked siRNA [133].  Thus, siRNA needs a protective carrier capable of targeting the cell of 
interest.  
There are two main categories of carrier systems for the delivery of siRNA -  viral and non-viral 
based vectors. The viral vectors present some limitations such as the difficulty of the vector 
production, broad tropism and ability to trigger the activation of the immune system. Certain viral 
vectors were found to be carcinogens and have insufficient space for packing large quantities of 
siRNA [134]. Non-viral vectors are simpler to synthesize, can load more genetic material and have 
less immunogenicity [134]. The non-viral vectors include lipid-based transfection reagents, 
macromolecule nanocarriers, and polymer-based NPs. 
Polymer-based NPs as a vehicle for siRNA delivery are often used in the past several 
decades. Poly(lactic-co-glycolic acid) (PLGA) is an example of a FDA approved biodegradable 
and biocompatible polymer, extensively used to deliver siRNA. PLGA demonstrated an enhanced 
efficacy to encapsulate small molecules, nucleic acids, and proteins. Furthermore, PLGA NPs are 
easy to customize to attached targeting moieties at the surface and also used for imaging [135]. 
Solid lipid nanoparticles (SLNs) have also gained a lot of interest in the past decade. The lipid-
based nanocarriers may be composed of a solid lipid core dispersed in an aqueous surfactant 
solution at room temperature. The surface of SLNs can be modified to attach targeting moieties 
for the drug to be released in a specific type of cell. SLNs are easy to synthesize using techniques 




 pH-responsive polymers  
Polymeric materials that are capable of responding to external physical and chemical 
stimuli such as pH, ionic strength, light, electric field, and temperature by changing their behaviors 
are extensively investigated in pharmaceutics and medicine [137, 138]. pH-responsive polymers 
are defined as materials that can respond to the pH changes of the surrounding medium by varying 
their morphologies and conformations due to the protonation-deprotonation equilibrium of the 
functional groups in the polymer chains [139]. Cationic pH-sensitive polymers will have a 
different response than anionic pH-sensitive polymers in various pH buffers. For example, 
poly(acrylic acid) contains carboxylic acid groups (-COOH) that are ionizable at basic pH. In 
contrast, poly(N,N'-diethyl-aminoethyl methacrylate) has amino groups (-NH2) that are ionized 
and dissolves at acidic pH [140]. A pH-responsive polymer, cellulose acetate phthalate (anionic 
pH-responsive polymer) was used to coat vaginal tablets to provide a slow release of IQP-0528. 
The antiretroviral (IQP-0528) presented a slow release at the acidic pH (vaginal < pH4.5) and 
provide burst release at pH> 7.2 mimicking the presence of semen in the vaginal tract [141, 142]. 
This controlled release prevents a continuous exposure of the drug to the vaginal tract when not 
necessary (absence of sexual intercourse) and provide a high release in the presence of semen 
during sexual intercourse. 
In our study, we will use polyacid polymers for triggering drug release only when the pH 
of FGT increases to mimic the presence of seminal fluid.  At low pH, polyacid polymers will not 
swell because of the protonation of the acid group, hence ionized. When the pH increases, the 
acidic group will be deprotonated and become negatively charged. The repulsion between those 
negative charges makes the polymer swell to make bigger pores with a subsequent release of all 
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the entrapped molecules.  The release of a therapeutic compound at desired pH (pH>6) will greatly 
decrease the amount of drug used and reduce unnecessary toxicity.  
 
1.2. Immunocompromised patients and chronic wounds  
 Chronic Wound 
Chronic wounds or non-healing wounds are those that do not progress through the healing 
process in a timely manner and turn into a severe healthcare concern [143]. Individuals with low 
immune profiles tend to not be able to heal properly. Immunocompromised patients tend to 
develop bacterial infections, diabetes, and other comorbidities [144]. Those comorbidities can 
cause chronic wounds [145]. People infected with HIV can easily develop chronic wounds and are 
more susceptible to develop wound complications after surgery [146, 147]. For example, Popovich 
et al. showed the colonisation of HIV-infected patient body by methicillin-resistant staphylococcus 
aureus [148]. This colonization makes it easy to infect a wound on HIV patients and establish a 
biofilm. Chronic wounds include diabetic ulcers, vascular ulcers, and pressure ulcers [149]. 
Diabetic foot ulcers will affect almost 15% of people living with diabetes, and the recurrence of 
these wounds is seen in over 70% of patients within five years [150]. Diabetes causes arterial 
damage and neuropathy that can create ulcers in the foot area. Often, bacterial infections can 
worsen those ulcers and spread them to the bone of the foot [151]. In the case of vascular ulcers, 
which are mostly associated with venous diseases, venous stasis can create damage to the venous 
systems of the leg and cause hypertension and reduce blood flow [152].  Pressure ulcers or 
bedsores are ulcers resulting from prolonged pressure on the skin commonly seen in patients with 
reduced mobility like in residential care homes or hospitals [153]. Although researchers know the 
classifiable cause of the ulcer capable of creating a chronic wound, resolving the underlying cause 
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will not necessarily lead to healing [149]. In this thesis, we propose to develop a new scaffold 
made of a thermo-sensitive material that can rapidly release an active compound formulated into 
a NP for targeted and prolonged release inside the biofilm. The NP with sustained-release will 
increase the exposure of the active compound to the bacteria which might help destroy the bacteria. 
The thermo-sensitive material will be gel-based at room temperature to hold the NPs. Upon 
application on the skin, the temperature will rise and the gel will liquefy allowing the release of 
NPs. It is also important that the wound dressing/scaffold for delivering the active compound is 
easily removed without causing any pain or the reopening of the wound. This new scaffold design 
will not stick to the wound and won't reopen it when it is taken off.  
  
 Physiology of wound healing  
The wound healing will occur through a systematic process of 4 overlapping phases: 
Hemostasis, inflammation, proliferation, and maturation [154]. After an injury, the 
vasoconstriction of the blood vessel and blood clot will occur through the hemostasis phase to 
prevent blood loss. The thrombocytes (platelets) at the site of the injury produce growth factors 
and cytokines to attract endothelial cells, immune cells, and fibroblasts. This will initiate the 
inflammatory phase carried out by neutrophils and macrophages [149]. Neutrophils are the first 
on-site responding to platelet degranulation, complement activation, and bacterial degradation. 
Neutrophils will produce proteolytic enzymes like matrix metalloproteases (MMPs), elastase, 
cathepsin G, anti-microbial proteins (AMPs; multi-functional cationic peptides capable to induce 
cytokines production, to attract immune cells, and directly kill pathogens and promote wound 
healing), reactive oxygen species (ROS) and cytokines in an effort to clean the wound bed [155]. 
While wound healing is progressing, neutrophils are slowly replaced by monocytes, which will 
differentiate and become macrophages to continue the cleaning process by phagocytosis of 
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microorganisms. The macrophages are sensitive to their environment via Toll-like receptors, 
complement receptors, and Fc receptors. The inflammation phase will end with the apoptosis of 
immune cells [156]. The third phase of the healing process, the proliferation phase, is characterized 
by tissue granulation, angiogenesis (new blood vessels), and epithelialization. This phase overlaps 
with the last phase where remodeling will assist in the wound contraction, collagen remodeling, 
and extracellular matrix degradation [155].  
 
 Chronic wound vs Acute wound 
Unlike acute wounds, chronic wounds do not follow the standard wound healing process. 
Chronic wounds present a persistent pro-inflammatory phase that prevents the wound from 
healing.  This persistent inflammatory phase is mostly due to repetitive tissue trauma, tissue 
hypoxia, tissue breakdown and necrosis, and more importantly, a substantial bacterial burden 
[157]. There is an imbalance in the production of pro-inflammatory cytokines, chemokines, 
proteases.  Neutrophils and activated macrophages present at the wound site release pro-
inflammatory cytokines TNF-alpha and IL-1 beta that increase the production of MMP and reduce 
the synthesis of tissue inhibitors of metalloproteinases (TIMPs), which will induce more 
degradation of extracellular matrix (ECM), reduce fibroblast proliferation and collagen 
synthesis[158]. Immune cells also will produce ROS intended to provide defense against 
microorganisms in low concentrations. But in the case of chronic wounds, the production of ROS 
is exacerbated and causes damage to ECM proteins and cells [159].  Another downside of chronic 
wounds is the massive presence of senescent cells with impaired proliferation and secretory 
capacities. In fact, those cells are very slow or completely unresponsive to wound healing signals 
with a limited cell proliferation capacity that impedes wound healing. It has been reported that the 
senescent phenotype of cells, in this case, is due to the DNA damage caused by oxidative stress or 
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abnormal metabolic changes observed in diabetic patients. In this regard, recent researchers have 
focused on mesenchymal stem cell applications in chronic wound healing [160]. They developed 
a scaffold that mimics the dermal structure and uses it to deliver mesenchymal stem cells to the 
wound bed. Those cells have the ability to differentiate into various cell types and also can recruit 
different cells needed for faster regeneration [160].   
 
 Biofilms and inflammation in chronic wounds 
Biofilms consist of microorganisms (bacteria or fungi) enclosed in an extracellular matrix 
composed of hydrated polymers and debris. The bacteria in biofilm differ from their planktonic 
peers in structure, genetic make-up, interaction with the host, and resistance to antibiotics [161]. 
Mature biofilm formations are more resistant to antibiotics than younger, less established biofilms. 
The bacteria separated from the biofilm or if the biofilm is re-suspended in culture media, increase 
the vulnerability to antibiotics [162]. The presence of necrotic tissues and impaired host immune 
system make the chronic wound an ideal environment for bacterial growth and biofilm 
implantation. About 60% of chronic wounds are populated with biofilms compared to 6% in acute 
wounds [163]. Studies have shown that the biofilm formation inside chronic wounds is due to the 
concerted action of many bacterial species instead of only one. The most populated bacteria found 
in wound biofilms are Pseudomonas, Staphylococcus, Janthino-bacterium, Corynebacterium, and 
Propionibacterium acnes. The amount of different bacterial species present in a wound is highly 
dependent for each specific patient case [155, 164, 165]. The biofilm presence in chronic wounds 
plays a critical role in the prolonged inflammatory phase as discussed above, such as the excessive 
release of cytokines, the extended presence of neutrophils and macrophages, the changes in oxygen 
concentration, and the pH in the wound [166]. A chronic wound with biofilm present shows much 
more neutrophil infiltration. For example, Pseudomonas attracts neutrophils in the wound area 
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using their quorum-sensing system and lyses them [167]. These bacteria protect themselves from 
phagocytosis by neutrophils through their rhamnolipid protective shield. The bacterial DNA in 
biofilm also is reported to stimulate neutrophils [167].  Another example of a study conducted on 
a mouse model shows that the presence of Staphylococcus aureus in the wound was capable of 
exacerbating macrophage infiltration but changing their function by suppressing microbicidal 
activity and increasing cell death [168]. The inflammatory cytokines are increased dramatically by 
the presence of biofilms as depicted by a study showing the levels of IL-2, IL-4, IL-6, IL-12, IL-
17, and TNF- α caused by the presence of S. aureus [169]. MMP-1 and MMP-3 production were 
increased using in-vitro keratinocyte culture challenged with biofilm [170]. From these 
observations, microbial presence appears to contribute to the prolonged inflammatory phase. 
Eliminating the microbial growth from the surface of chronic wounds will tremendously speed up 
the wound healing process. Unfortunately, the bacteria present in a biofilm have particular 
resistance to antibiotics, which seems to be an important mechanism for biofilms survival. The 
extracellular polymeric substance might prevent the efficient diffusion of antibiotics. Also, 
antibiotics act on metabolic activities, and unfortunately, since bacteria present in a biofilm are 
quiescent with slow metabolic activity, the antibiotics will tend to be ineffective. The stress 
response, nutrition supply, and oxidative stress may induce mutations to the bacteria and slow 
down growth and metabolic activity making them resistant to antibiotics. Besides surgery, which 
is the most effective way of treating chronic wounds, other current strategies used for biofilm 
disruption and wound treatment, are summarized in Table 1.4. As suggested by Zhao et al., to be 
able to kill microorganisms in a biofilm, a high dosage of the medication applied directly on the 




Table 1.4: Current therapies for treating chronic wounds  



















No Not significant at low 
concentration 
Development of 













solutions may block 
microbial attachment 
to surfaces;  
 
Low concentrations of 
betaines and biguanides 
may not harm host tissue, 
depending upon chemical 
structure. 
Poor chance of 
development of 
resistance to PHMB; 
resistance not reported. 
Collagen with 
PHMB [171] 






Unknown Poor chance of 
Development of 
resistance to PHMB; 
resistance not reported. 
Hypochlorite 
[172] 
Bleach; chlorine Yes at high 
concentration 
May induce tissue injury 
associated with 
inflammation; toxic to 
fibroblasts and 
keratinocytes. 
Reports of development 
of acquired resistance 
to certain pathogens to 
chlorine are very 
limited. 
Silver [173] Ionic silver; 
silver sulfadiazine 
No Silver nitrate and silver 
dressings have been 
found to be cytotoxic in 
vitro. No in vivo data 









No Various concentrations of 
topical antibiotics have 




increased use of 
neomycin, bacitracin, 
and mupirocin. 
Iodine [175] Cadexomer iodine Limited in vivo, and 
in vitro evidence that 
cadexomer iodine 
reduces biofilm in 
wounds and may 
destroy biofilm 
structures 
May be safe for host, but 
controversies remain 
regarding potential 
cytotoxicity and systemic 
absorption with 
prolonged use 
No bacteria resistance. 
Iodine-resistant 




 Thermo-responsive polymer scaffold  
A thermo-responsive polymer will undergo property changes upon changes in temperature. 
There are two different groups of thermo-responsive polymers: a group that forms solution upon 
heating, and a group that forms solution upon cooling. The polymer that forms solution upon 
heating present an upper critical solution temperature (UCST) and the opposite group presents a 
lower critical solution temperature (LCST) in their phase diagram [176]. An excellent review by 
Aseyev et al. discussed the extensive applications of thermo-responsive polymers used in 
chromatography, temperature-triggered drug release, bio-separation, targeted drug delivery just to 
name a few [177].  
In our study, we will design a wound dressing using gelatine as a thermo-responsive 
material to help deliver the medication to biofilms present in chronic wounds. Gelatine has an 
UCST of around 32C, which is slightly closer to the skin temperature of 33C. Gelatine is derived 
from collagen extracted from connective tissues, skin, and bone of animals. The gelatin has a triple 
helix chain in the form of a coil conformation. When the gelatin is heated past its melting 
temperature, the hydrogen bonds between the chains become fragile and disordered and turn to a 
liquid form. Upon cooling, the gelatin can revert to its triple-helical state [178]. The amplitude of 
the gelatine helical state transformation depends on the concentration, temperature, stress, solvent, 
and the presence of crosslinking agents [178]. Gelatin has been extensively used as a drug delivery 
material since it is natural, biodegradable, biocompatible, easy to modify and safe [179-181]. 
In this study, we propose a combination therapy consisting of the delivery of vancomycin 
and LL37, encapsulated in SLN formulated in a thermo-responsive gelatin scaffold for rapid 




1.3. Project rationale, hypothesis and objectives. 
Project #1: 
 
The first part of my thesis focused on the development of a microbicide in an effort to 
prevent HIV infection. In the absence of an effective vaccine, they are an excellent alternative to 
condoms to help reduce male-to-female transmission. Unfortunately, several microbicide trials 
previously demonstrated limited efficacy due to the fact that gel dosage forms are messy, can be 
easily “washed out” of the FGT, and requires high patient compliance (e.g. gel needs to be applied 
before and after sexual intercourse) [182]. An IVR can be a suitable alternative strategy that can 
provide controlled, sustained delivery (>14 days) of drugs within the FGT [183]. In this project, 
we propose to develop a segmented combination IVR whereby one-half of the IVR will be loaded 
with HCQ and the other half of the IVR will be coated with a pH-responsive film for the rapid 
release of small interfering RNA (siRNA)-encapsulated nanoparticles as a novel strategy for 
protecting against HIV infection. It is widely documented that drug resistance is a concern with 
conventional antiretroviral therapy. As a result, delivering a combination of drugs of different 
classes (e.g siRNA and chemotherapeutics) targeting different steps in the HIV infection process 
is expected to be more effective. Studies have shown that quiescent (resting) CD4+ T cells are less 
susceptible to HIV infection [184]. HCQ is an immunomodulatory drug approved for the treatment 
of malaria, systemic lupus erythematous, and rheumatoid arthritis [185]. It is capable of reducing 
HIV viral load and the activation of T-cells, resulting in reduced viral infection [186, 187]. While 
T-cells are activated, there will be an increased expression of cell surface markers such as HLA-
DR, CD69, and CD38 increasing the susceptibility for HIV infection [188]. HCQ at has the ability 
to increase the lysosomal pH and impairing the expression of T-cells activation markers such as 
HLA-DR, CD69, and CD38 [189]. In addition, HCQ has been shown to inhibit the production of 
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HIV-1 gp120 by increasing the lysosomal pH of the cell and altering the enzymes required for 
glycoprotein 120 production [190]. RNA interference via the use of siRNA is a strategy for 
knocking down gene expression. When there are no drugs available to act on a specific target, 
using siRNA as a therapeutic agent could be a highly effective alternative. Furthermore, siRNA 
can be designed to specifically target the knockdown of a single gene, reducing systemic toxicity 
and off-target effects associated with conventional drug therapy. Unfortunately, siRNA cannot 
readily traverse cell membranes, hence, a drug carrier such as nanoparticles is required for 
delivering siRNA into the cytosol of the target cells. In this project, solid lipid nanoparticles (SLN) 
encapsulated with CCR5 siRNA will be functionalized with anti-CD4 antibody to specifically 
target and deliver to CD4+ immune cells (HIV target cells) and knock down the expression of 
CCR5, a co-receptor involved in HIV-1 infection.  
Hypothesis:  
It is expected that at normal vaginal pH (3.5-4.3) there will be no release of siRNA-loaded 
nanoparticles. During heterosexual intercourse, the vaginal pH becomes elevated due to the 
presence of seminal fluid, resulting in elevated pH (>6.2) [191]. As a result, it is expected that at 
pH>6.2, the IVR will provide rapid release of siRNA-nanoparticles while HCQ will be released 
continuously (>14 days) at both acidic and neutral pH to prevent immune activation of T-cells.  
Specific Aims: 
1) Develop and characterize a segmented combination pH-responsive IVR delivery system. 








The second part of my thesis focused on the development of a thermo-responsive chronic 
wound dressing designed to reduce biofilm formation on chronic wounds and facilitate the healing 
process. The current and widely used wound dressings present some disadvantages. For example, 
gauzes are dry and not able to maintain the optimum moisture of the wound bed and can easily 
adhere to the wound which makes it difficult to remove without creating another trauma with 
residue remaining into the wound [192]. The current hydrogel wound dressings have been found 
to be non-adherent with a high water content that reduces their absorptive ability therefore cannot 
be used on wounds with high exudate [193]. An ideal wound dressing as described by Sood et al, 
should provide an optimum moist environment capable of removing excess exudate, protect the 
wounds, can conform to wound shape, and should be easy use and to remove without trauma [192].   
In this project, I propose the development of a thermo-responsive hydrogel dressing made 
of gelatin-chitosan capable of delivering SLN containing LL37 and vancomycin to reduce the 
bioburden and improve wound healing. Vancomycin and LL37 SLN have been shown to 
synergistically enhance antibacterial activity against S. aureus [194]. LL37 is derived from the 
cathelicidin precursor protein hCAP18 produced by human neutrophils, mast cells, and natural 
killer cells. Proteinase 3 cleaves hCAP18 and the C-terminal becomes LL37 with 37 peptides[195, 
196]. Although LL37 has been shown to promote wound healing while acting on cell proliferation, 
differentiation, it is also a potent anti-microbial [197, 198]. Shahmiri et al, showed that LL37 
exhibits two different modes of action against bacteria. The peptide might interact with bacteria 
membrane can create pores in bilayers of unsaturated phospholipids or can create the formation of 
tubular structures by acting like a membrane modulating agent [199]. On the other hand, 
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vancomycin is a glycopeptide that has been used for many decades. It has been shown to be very 
potent against gram-positive bacteria. Vancomycin binds to the acyl-D-ala-D-ala portion of the 
bacterial peptidoglycan cell wall and prevents their cross linking altering the cell wall formation. 
The bacterium reacts by producing more peptidoglycans that accumulates and triggers an enzyme 
against the peptidoglycans which contributes to the breakdown of the cell wall [200, 201].  The 
use of LL37 alongside vancomycin might improve biofilm reduction and promote wound healing.  
Hypothesis: 
The development of a thermo-responsive hydrogel scaffold capable of delivering 
LL37/vancomycin-SLNs upon application on a chronic wound will be capable of decreasing the 
biofilm burden and potentially enhance wound healing.  
 Specific Aims: 
1) Preparation of LL37 and vancomycin encapsulated SLNs  
2) Preparation of a thermo-sensitive scaffold from gelatin and chitosan to incorporate the 
SLNs. 
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In this study we investigated the viscoelastic and mechanical behaviour of polyvinyl 
alcohol (PVA) films formulated along with carrageenan, plasticizing agents (PEG and glycerol), 
and when loaded with nanoparticles (NP) as a model for potential applications as microbicides. 
The storage modulus, loss modulus and glass transition temperature were determined using a 
dynamic mechanical analyzer (DMA). Films fabricated from 2% and 5% PVA containing 3 mg or 
5 mg of fluorescently-labeled NPs were evaluated. The storage modulus and loss modulus values 
of blank films were shown to be higher than the NP-loaded films. Glass transition temperature 
determined using the storage modulus was between 40-50C and 35-40C using the loss modulus. 
The tensile properties evaluated showed that 2% PVA films were more elastic but less resistant to 
breaking compared to 5% PVA films (2% films break around 1N load and 5% films break around 
7N load). To our knowledge, this is the first study to evaluate the influence of NP and film 
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Polymeric films are increasingly gaining attention as drug delivery systems due to their 
ability to provide rapid drug release and bio-adhesive properties that may increase the retention 
time at the target tissue. Film-formulated products offer user compliance as well as ease of 
application. Recently, a number of researchers have focused on the development of polymeric 
vaginal films as contraceptives and microbicide formulations [202-206].  The potential of vaginal 
films for contraceptive or microbicide applications is mainly due to their ability to overcome 
several challenges related to acceptability, compliance, and efficacy in comparison to gel-based 
formulations [206-208]. For example, gels are messy and may leak resulting in reduced drug 
concentrations. Despite films demonstrating to be a promising drug delivery platform, the type of 
bioactive being delivered will affect the mechanical, chemical and physical properties of the film, 
which in turn will also alter drug release rates [208]. 
Polyvinyl alcohol (PVA) is a polymer that is widely used in a variety of applications due 
to its biodegradability and its ease in preparation [209]. PVA is a water-soluble and crystalline 
polymer. This material can form films that are biocompatible with good mechanical properties 
allowing its use in various industrial and medical applications. It has been used in pharmaceutics 
as a drug delivery system due to its high water solubility and rapid disintegration rate [204, 210]. 
Polymeric films can be designed to be highly resistant to repeated flexure or creasing [211]. Some 
of the film properties such as tensile strength, and permeability to gases or water vapour may be 
important features to consider when developing a drug delivery system [212]. Studies have shown 
that thin polymeric films tend to degrade in the presence of destabilizing forces such as heat and 
mechanical stress at the film’s interface [211, 213]. Quantitatively, such instabilities affect the 
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thermal and mechanical characteristics of the film [211, 213].  Depending on the plasticizer, 
excipients, or drug loaded into the films, it can exhibit different physico-chemical behaviours.  
Numerous studies are using polymeric film formulations to deliver nanoparticles (NPs) 
[214, 215]. The nanocarrier is used to protect the active compound from its external environment, 
can assist in active targeted delivery, and can provide controlled, sustained drug release [216]. 
They have been used to address the concerns of physicochemical instability of drugs, low cellular 
uptake and the need for multiple dosing [217]. For example, different PVA films with different 
thickness have been formulated to deliver varying concentrations of poly(D,L-lactic-co-glycolic 
acid)-poly(ethylene glycol) NPs containing siRNA as a therapy for preventing HIV infection 
within the female genital tract [205].  
Hence, the objective of this study was to experimentally determine the influence of NP 
content and film composition on the physico-mechanical properties of NP-loaded PVA films 
subjected to varying temperature ranges. 
 
 Materials and Methods 
Degradex® fluorescent PLGA NPs were purchased from phosphorex (Hopkinton, 
Massachusetts, USA). PVA (98-99% hydrolyzed; MW 31,000-50,000) and λ-carrageenan were 
purchased from American Custom Chemicals Corp (San Diego, CA, USA). Phosphate-buffered 
saline (PBS; pH 7.4) was purchased from Lonza (Allendale, NJ, USA).  Double distilled water 






 Preparation of nanoparticle-loaded film  
PVA films were prepared by a solvent casting method as previously described [205]. 
Briefly, PVA and carrageenan were dissolved overnight in distilled water at 80C. The PVA 
solution was allowed to cool down to room temperature and diluted to either 5% or 2% solution 
(w/v). 240 L of glycerol and 80 L of PEG400 were mixed in 8 mL of the solution and allowed 
to stir for 1h. Commercially available fluorescent NPs (200 nm) were added and mixed for an 
additional 1h to prepare 5% film containing NPs with the ratio of 1:88 [w (NP)/w 
(PVA+carrageenan)] for 5 mg NPs loading and 1:146.6 for 3 mg NPs loading. For the 2% film 
solution, a ration of 1:40 and 1:66.6 were used for 5mg and 2 mg NPs loading respectively. 
Fluorescent Degradex® PLGA was made by Phosphorex Inc by standard oil/water emulsion and 
encapsulating a hydrophobic dye.  The mixture was poured into a TeflonTM dish (30 cm2) and 
placed in the oven at 40C overnight to evaporate the solvent and to form the film. 
 
 Dynamic mechanical analysis 
Dynamic mechanical analysis (DMA) of the films was performed using a DMA Q800 
(TA Instruments, New Castle, USA) in tensile mode. Film samples (2% and 5% PVA blank 
films or NP-loaded films) were cut into sizes between 5-6.5 mm in width, 20-30 mm in length, 
and 0.5-0.7 mm in thickness in order to conform to the dimensional limits required for the tensile 
film clamp test fixture. The average thickness for each film sample was based on three separate 
measurements, taken at the two ends and in the middle. The DMA test procedure was as follows: 
after mounting the film sample on the DMA tension film clamp, the furnace was sealed and the 
mechanical properties were measured from 25 ºC to 80 ºC at a ramp rate of 3 ºC per min under a 
preload of 0.5 N. Measurements were performed at a constant frequency of 1 Hz and strain 
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amplitude of 10 μm. This setup was used to determine the glass transition temperature and the 
real (storage) modulus E´, imaginary (loss) modulus E´´ using thermal analysis software (TA 
Instrument Universal Analysis 2000) included with the DMA apparatus to analyse the data. The 
software automatically detects using the signal change on the analysis curve. The inflection point 
on the curve of the modulus can be considered as the glass transition and it is determined by 
using the tangent of the onset point and the end point [218, 219].  3 different were performed for 
each film formulation throughout this paper.  
 
 Determination of the glass transition temperature (Tg) 
The DMA machine was set to the multi-strain mode using the tensile film clamp at a single-
frequency temperature ramp of 1 Hz and a ramp rate of 3ºC per min. The glass transition 
temperature was recorded at a temperature range of 25 ºC to 80 ºC using a ramp rate of 3 ºC per 
min, a fixed frequency of 1 Hz and amplitude of 10 µm. 
 
 Determination of storage and loss modulus  
Using the tensile film clamp, the DMA machine was set to the multi-strain mode. The real 
(storage) modulus E´, imaginary (loss) modulus E´´, and loss factor tan δ were recorded as a 
function of increasing temperature from 25 ºC to 80 ºC using a ramp rate of 3 ºC/min, a fixed 
frequency of 1 Hz and an amplitude of 10 µm using thermal analysis software (TA Instrument 






 In vitro drug release 
PVA film samples (2% and 5% fluorescent NP-loaded films cut to around 20 mg) were 
suspended in 1 mL release medium (PBS pH 7.4). The fluorescent NP-loaded film suspension was 
transferred to an orbital shaker maintained at 37 ºC at a speed of 100 rpm (VWR, Edmonton, 
Canada). 200 µL aliquot of samples were periodically removed for analysis and were replenished 
with equal volume of fresh medium. The fluorescent NP concentration in the samples was analyzed 
on a microplate reader (BioTek Synergy) with an excitation wavelength of 530 nm and an emission 
wavelength of 590 nm. Samples were taken and analyzed in triplicate for each time point. Films 
disintegration have been evaluated also by immersing 50 mg of each film in 3 mL of ddH2O in 20 
mL vial and place in the orbital shaker at 37 ºC at a speed of 100 rpm. Visual inspection is used to 
record the disintegration rate.   
 
 Determination of mechanical properties 
Mechanical analysis was performed on an Instron tensile machine model 5943 with a 
crosshead speed of 100 mm/min and a force of 1 kN at room temperature. All the film samples 
were cut into rectangular shapes with a length of 300.3 mm, a width of 6.800.7 mm, and a 
thickness of 0.07 mm for the 2% film and a thickness of 0.16 mm for the 5% film.  
 
 Scanning electron microscopy 
Scanning electron microscopy (SEM) studies were carried out using a Quanta 650 FEG 
equipped X-ray microanalysis with low-vacuum capabilities at a voltage of 10 keV. Film samples 
were cut into small pieces and attached to slab surfaces with double-sided adhesive tape. 
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 Statistical analysis 
Data are presented as mean ± standard deviation (SD). The n-value refers to number of 
replicates performed for each study. One-way ANOVA was performed on all results, with P<0.05 
considered to be significant. 
 
 Results 
The storage and loss modulus of various 2% and 5% PVA film formulations were 
determined (Figure 2.1). Based on the results, the storage modulus for both 2% and 5% blank films 
were slightly higher than their counterpart films loaded with NP. The storage modulus of 2% blank 
film varied between 22.35 to 13.93 MPa for a temperature ramp from 30C to 60C and 
143.2414.18 to 82.635.43 MPa for 5% blank film at the same temperature ramp. Furthermore, 
the storage modulus for films containing 3 mg of NP was also higher than the ones containing 5 
mg of NP. PVA films containing 3 mg and 5 mg of NPs vary between 15.672.08 to 10.071.35 
MPa and 12.725.29 to 8.153.70 MPa, respectively. The storage modulus decreased gradually as 
the temperature increased. The mean storage and loss modulus are presented in Figures 2.2A and 
2B, respectively. The sharpest slope of the storage modulus (detected by TA Instrument Universal 
Analysis 2000 software) was used to determine the glass transition temperature where the film 
began the transition from a glassy state to a more rubbery state.  The mean glass transition 
temperatures for each film as determined using the storage modulus is presented in Figure 2.2A. 
As can be seen in Table 2.1, 2% PVA films loaded with either 3 mg (53.25±2.86 C) or 5 mg 
(54.10±7.63C) NP exhibited higher mean glass transition temperatures compared to 5% PVA 
films with 3 mg (40.05±2.09C) or 5 mg (42.07±2.21C) NP, respectively (Table 2.1), when using 
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the storage modulus for determination. In contrast, no significant differences were observed in any 





















Figure 2.1: Determination of storage and loss modulus of film samples (Plot from DMA 
analysis software).  Variation in (A) storage and (B) loss modulus for 2 and 5% PVA blank films 






Figure 2.2: Determination of storage and loss modulus of film samples.  (A) storage modulus 
and (B) loss modulus of 2% and 5% PVA films loaded with 3 mg or 5 mg NPs.  Data represent 




Table 2.1: Glass transition temperature determined using two different parameters  
(A) storage modulus and (B) loss modulus. Data represent mean SD (N=3).  
 
Glass Transition (C) Blank Film 3mg NP loading 5mg NP loading 
2% PVA film 37.94 ±0.1 36.89±3.48 40.14±4.01 
5% PVA film 36.88±1.4 37.81±0.12 37.7±0.32 
  
Disintegration studies were performed on blank PVA films and films loaded with 3 or 5 
mg of NP. 50 mg of each film was immersed in 3 mL of PBS buffer and placed in an incubator 
shaker at 37oC and 100 rpm (Table 2.2). 2% PVA films with 3 or 5 mg loading disintegrated within 
3 hr making the medium cloudy. The 5% PVA films containing 3 or 5 mg loading partially 
disintegrated even after 24 hours with no changes to the transparency of the medium.  
 
Table 2.2:  Disintegration time for PVA films. 
PVA films 2% blank 2% film + 
3mg NP 
2% film + 
5mg NP 
5% blank 5% film + 
3mg NP 












Glass Transition (C) Blank Film 3 mg NP loading 5 mg NP loading 
2% PVA film 39.61 ±2.76 53.25±2.86 54.10±7.63 







In vitro release studies were performed on different film preparations. The amount of 
fluorescent NPs released was evaluated using a microplate reader (Figure 2.3). Figure 2.3 
represents the release obtained from 2% PVA films loaded with 3 mg or 5 mg of NPs and 5% films 
loaded with 3 mg or 5 mg. 2% films demonstrated a release of 18.925.6 g (8.70.7 %) for 5 mg 
NP loading and 11.481.5 g (9.80.5 %) for 3 mg NP loading after 4 hours followed by a slow 
and negligible release up to 24 hours. There was a slow release of NPs up to 24 hours with 6.80.8 
g (3.250.39%) for 5% film formulation containing 5 mg NPs loading and 4.130.36 g 













Figure 2.3: In vitro cumulative release of 2% and 5% PVA films loaded with 3mg or 5mg 
fluorescent NPs. (A) Amount of NP released (B) Percentage of NPs released. Data represent 




Tensile properties such as Young’s modulus, maximum load at break, tensile strain at 
maximum load and tenacity (used to measure the overall strength) of the film at maximum load 
has been calculated from stress-strain curves (Table 2.3). 2% blank films have a tensile strain at 
maximum load of 0.162 mm/mm, and 0.151 mm/mm for films containing 3 mg NP loading and 
0.134 mm/mm for films containing 5 mg NP loading. The 5% blank films demonstrated to have 
lower tensile strain and started to break at 0.037 and 0.043 mm/mm for the 3 mg and 5 mg NP 
loading, respectively. 2 % PVA films present more elasticity but start breaking at lower load, 
around 1N compared to 5% PVA film, which started to break around 7N. The 5% PVA film is less 
elastic, and broke at only 1 mm of the crosshead displacement distance compared to the 2% film 
which broke after 4 mm of extension. 
 
Table 2.3: Mechanical properties measured at room temperature for 2% and 5% PVA films 
loaded with 3 mg or 5 mg NPs. Data represent mean SD (N=3). N/Tex= Tenacity; Maximum 




























2% blank 36.83±5.03 1.2±0.1 10.5±2.4 13.1±2.78 1.14±0.14 
2% film + 
3mg NP 
41.03±5.36 0.86±0.15 7.36±0.77 16.23±2.5 1.16±0.2 
2% film + 
5mg NP 
41.36±4.92 1±0.2 8.33±1.15 13.8±2.42 1.06±0.05 
5% film 
blank 
28.76±1.5 7.23±0.49 128.2±18.37 5.24±0.87 7.68±0.72 
5% film + 
3mg NP 
28.03±5.46 6.1±1.1 153.66±15.97 4.63±0.86 6.61±0.98 
5% film + 
5mg NP 





Figure 2.4: Tensile strain of 2% and 5% PVA films loaded with 3 mg or 5 mg of NPs. The 
onset point represents the moment the film started to tear. Load in Newton (N).  
 
The surface morphology of each film was visualized by their SEM images. The 2% blank 
film presents some porous structure, which is less obvious on 3mg and 5 mg NP, loaded films. The 








Figure 2.5: SEM images of 2% and 5% PVA films containing 3 mg or 5 mg of NP loading 
(2000 X).  
 
 Discussion  
Vaginal films have been developed for multiple purposes and present many advantages, 
but the films must be designed in a specific way to be acceptable, usable, and stable [220]. For 
vaginal films, it must possess certain characteristics so that it will not cause irritation or toxicity, 
must be flexible enough to be easily handled by the patient and more importantly, must allow the 
active compound to be released at a given time frame for a therapeutic effect. In this study, we 
determined the mechanical properties of PVA films containing NPs as previously developed [205]. 
The film formulation using PVA and two different plasticisers (PEG 400 and glycerol) produce 
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films that are smooth and slightly transparent. Different percentages of PVA produced different 
film thicknesses, which can play an important role in the thermodynamic properties of a film. In 
this study, we maintained the quantity of plasticisers constant and changed the amount of PVA or 
NP loading and evaluated its effects on the mechanical properties of the films. The disintegration 
study presented in Table 2.2 showed that the 2% PVA film formulation broke down completely in 
3 h. The amount of NPs loaded into the films appeared to have no impact on the rate of 
disintegration but in contrast, the ratio of PVA/plasticiser used had an influence. Jun-Seo et al 
(2000), reported that the plasticising effect of PEG400 on PVA will make the film more flexible, 
and disintegrate more easily [209]. The film formulation containing 5% PVA was composed of a 
lower ratio of plasticiser/PVA. These films were thicker, can swell and partially break down after 
24 h. A release study using fluorescent NP as presented in Figure 2.3 correlated with the 
disintegration study. The 2% film formulation, which disintegrated faster, showed the highest 
concentration of NPs released after 4 h. This release increased slowly until 8 h and remained 
constant until 24 h. The higher NP released represents a very low percentage which can probably 
be explained by a rapid decay of the fluorophore used to fabricate the commercial PLGA NP during 
the film fabrication process and the release study. Films loaded with 5mg of NP exhibited higher 
release of NP compared to 2% and 5% PVA films loaded with 3mg NP. Films formulated using 
5% PVA exhibited a lower NP release profile which appears to be related to the slower 
disintegration rate in comparison to 2% films. To further analyze the mechanical properties of the 
films, we used DMA to evaluate the storage modulus, which is a measurement of the elastic 
response of a material, and the loss modulus, which is the measurement of the viscous response of 
a material. Storage modulus and loss modulus are two parameters that we used to determine the 
transition temperature of the films. TA Instrument Universal Analysis 2000 software is used to 
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integrate all curves in order to determine the glass transition derived from the storage and loss 
modulus. From looking at Figure 2.1A the presence of NPs in the film matrix affect the physical 
properties of the film, in addition to plasticizers can reduce intermolecular forces, increasing the 
mobility of polymer chains. This can decrease the storage modulus of the film and also affect the 
glass transition temperature as described by Ding et al. [221]. Less plasticizer gave a higher storage 
modulus as seen in with the 5% PVA film formulation compared to 2%. Based on the results, it 
appears that as we incorporate more PLGA NPs into the matrix of PVA, it will tend to make the 
films less stiff. We also evaluated the loss modulus, which measures the energy dissipated as heat 
in order to determine the glass transition temperature of the polymeric film. Glass transition 
temperature determined using the storage modulus presents a transition state of blank films around 
40C. This transition state remained constant for 3 mg and 5 mg NP film loading in 5% PVA film 
formulation. A small increase in glass transition temperature was observed for 2% PVA films 
loaded with 3 and 5 mg of NPs, which is around 50C. This means that the 2 % PVA films loaded 
with NPs became more amorphous (semi-crystalline polymer) at a slightly higher temperature than 
5% films containing the same loading of NPs. This might be due to the restriction of the NPs on 
the mobility of matrix segments of the film [222]. We also determined the glass transition 
temperature using the loss modulus.  All the transition temperatures using the loss modulus 
occurred around 38C (Figure 2.2B). There was no significant difference between 2% and 5% 
PVA film formulations, either loaded with or without NPs. The amount of NPs loaded in the films 
did not have a significant impact on the glass transition temperature range. This shows that a 
transition takes place within the 38-50C temperature range. A wide temperature range was chosen 
(up to 80 ºC) to perform the thermal studies to mimic extreme conditions in which the film may 
potentially be subjected to e.g. countries with elevated ambient temperatures and inside a parked 
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car where the temperature can rise up to 80 ºC [223]. Those conditions will affect the film stability 
and in some cases render them unusable.  When looking at the mechanical properties of the films, 
2% films, which are very elastic due to the ratio of plasticizer present, were very fragile and broke 
at a load of 1 N. On the other hand, 5% films were less elastic because of the lower ratio of 
plasticizer but more rigid, so they break at a load of around 7 N. Compared to 2 % films, they 
supported a load higher than 6.5 N before breaking. The presence of NPs in the matrix of the films 
appeared to have no major effects on their elasticity. As revealed in the SEM images (Figure 2.5), 
the blank 2% PVA films appeared to have a more porous structure while 3 mg and 5 mg NP loaded 
films did not display this property. The porous structures, as explained by Ping et al., are probably 
due to the shrinkage of the film due to rapid water evaporation while exposed to heat during the 
film formation [224]. They further explained that under heat, the molecular chains of PVA are 
inclined to rearrange to form crystalline regions. This may also explain why NP loaded films do 
not reveal obvious pores since the presence of the NPs in the polymer structure will interact with 
PVA molecules to prevent shrinkage. The porous morphology is less obvious in 5% films since 
the PVA ratio is higher but some small pores are visible. Vaginal Contraceptive Film® (VCF) 
(Apothecus Pharmaceutical) is a commercially available PVA based filmed containing glycerine 
as a plasticiser and N9 as a spermicide [225]. This film has been reported to have a relatively hard 
texture and having sharp edges [226].  Those sharp edges and hard texture can potentially cause 
trauma to the female genital tract before the film is dissolved. In an effort to make our product 
softer and more pleasant for the user, we added PEG400 to supplement glycerol. The VCF film on 
the other hand exhibits faster dissolution compared to our formulation, which suggest that the 






The present study focused on the viscoelastic and mechanical behaviour of PVA films 
formulated along with NP for potential applications in vaginal drug delivery. The amount of PVA 
in the film formulation plays an important role on the film disintegration and the release of the 
NPs. The presence of the NPs in the film matrix did not alter much the mechanical behaviours. 
The presence of plasticisers, PEG 400 and glycerol enhance the films flexibility, which also play 
an important role in the rate of film disintegration and can influence the rate of NP release from 
the films. Hence, film formulations can be customized for the controlled release of NPs with the 
desired viscoelastic and mechanical properties suitable for vaginal drug delivery. 2% film 
formulation is ideal for a fast disintegration and drug release while 5% film formulation is ideal 
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3.1. Abstract  
 The use of polymeric devices for controlled, sustained delivery of drugs is a promising 
approach for the prevention of HIV-1 infection. Unfortunately, certain microbicides, when 
topically applied vaginally, may be cytotoxic to vaginal epithelial cells and the protective 
microflora present within the female genital tract. In this study, we evaluated the impact of 
hydroxychloroquine(HCQ)-loaded, reservoir-type, polyurethane intravaginal rings (IVRs) on the 
growth of lactobacillus crispatusandLactobacillusjenseniiand on the viability of vaginal and 
ectocervical epithelial cells. The IVRs were fabricated using hot-melt injection mold-ing and were 
capable of providing controlled release of HCQ for 24 days, with mean daily release rates of 
17.013.6g/mL in sodium acetate buffer (pH 4) and 29.454.84g/mL in MRS broth (pH 6.2). 
Drug-free IVRs and the released HCQ had no significant effects on bacterial growth or the viability 
of vaginal or ectocervical epithelial cells. Furthermore, there was no significant impact on the 
integrity of vaginal epithelial cell monolayers, in comparison with controls, as measured by 
transepithelial electrical resistance. Overall, this is the first study to evaluate the effects of HCQ-
loaded IVRs on the growth of vaginal flora and the integrity of vaginal epithelial cell monolayers. 
 
3.2. Introduction 
Based on a study conducted on 3400 women in the United States by the National Health 
and Nutrition Examination Survey showed that 29% of women within the age of 14-49 live with 
bacterial vaginosis (BV), the most common bacterial infection of the female genital tract (FGT) 
[227, 228]. It has been estimated that in 2014, more than 36.9 million people globally are infected 
with human immunodeficiency virus (HIV) [13]. More than 50% of those infected with HIV are 
women with heterosexual transmission as the main route of infection [229]. Despite the fact that 
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BV, HIV, and other sexually transmitted infections occur via the FGT, conventional treatment 
strategies involve oral administration of drugs. Most of these therapeutic strategies have failed 
because orally administered drugs can be highly metabolized by the liver before being absorbed 
into the systemic circulation and reaching the FGT. Increasing the administered dose may not be 
possible since this can result in severe systemic toxicity. The ideal treatment for infections or 
diseases affecting the FGT would be to deliver drugs locally via the vagina to increase therapeutic 
effects while reducing systemic toxicity.  
 Numerous intravaginal products have been developed for the treatment of local infections 
including semi-solid ointments, creams, suppositories, and vaginal gels [230, 231]. Studies have 
shown that patient compliance with respect to semi-solid dosage forms is low [232]. Major 
drawbacks include the fact that it requires daily applications, can be messy, and there can be 
leakage of the product resulting in reduced therapeutic efficacy. To overcome some of these issues, 
specialized drug delivery systems such as intravaginal rings (IVR) have been developed [68]. IVRs 
can be designed to provide sustained and controlled drug release, ultimately resulting in increased 
patient adherence [233]. To date, IVRs have been approved by the FDA for contraception and 
hormone replacement therapy  [234].  Recently, researchers have begun investigating the potential 
application of IVRs as microbicides (products applied topically vaginally for the 
treatment/prevention of sexually transmitted infections) and for the treatment of bacterial vaginosis 
[68, 235]. The major advantage of IVRs versus gels or tablets is the fact that IVRs can provide 
sustained release of drugs (>14 days) for long-term therapy, eliminating the need for daily drug 
administration [68, 236]. Once the IVR is self-inserted by the patient, it can remain within the FGT 
for prolonged periods of time and will not interfere with sexual intercourse [112]. Upon completion 
of the therapy cycle, patients can easily remove the IVR themselves. In order to develop an 
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effective IVR for therapeutic applications, it is important to take into consideration the nature of 
the drug and the chosen polymer used for IVR fabrication [67]. For example, IVRs must not have 
any significant effects on the normal flora of the FGT. Many microorganisms live in the FGT and 
protect the mucosal environment against pathogenic bacteria. Studies have shown that changes in 
the level of the lactobacillus family (most abundant flora in the vagina), will lead to the growth of 
pathogenic bacteria, resulting in inflammation of the FGT [237]. We have previously described 
the fabrication of a novel reservoir-type IVR for the controlled and sustained delivery of the 
immunomodulatory drug HCQ as a potential prevention strategy for HIV-1 [68]. The IVR 
demonstrated no significant impact on the viability of vaginal epithelial cells and on the production 
of pro-inflammatory cytokines in vitro. However, the effect of developed system on microflora 
and the integrity of vaginal epithelial cell monolayer were not addressed. Since these are critical 
parameters for the development of a biocompatible microbicide, the current study investigated the 
effects of drug-free IVRs and HCQ-loaded IVRs on vaginal lactobacilli, the main components of 
the normal vaginal flora, as well as the integrity of the vaginal epithelial cell monolayer. This is 
the first study to evaluate the effects of HCQ-loaded IVRs on the growth of vaginal flora. 
 
3.3. Materials and Methods 
3.3.1. Materials 
Lactobacillus jensenii (ATCC 55920) and Lactobacillus crispatus (ATCC 33820) were 
purchased from American Type Culture Collection (ATCC, Rockville, Maryland, USA). 
Lactobacilli MRS broth and agar were obtained from Thermo Fisher Scientific (Waltham, MA, 
USA). Medical grade non-biodegradable polyether urethane (PU) Tecophilic® HP-60D-35 and 
HP-93A-100 were purchased from Lubrizol (Wickliffe, OH, USA). HCQ was purchased from TCI 
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America (Portland, OR, USA). HPLC grade water, methanol, and acetonitrile were obtained from 
VWR International LLC (Batavia, IL, USA). MethocelTM K100M premium hydroxypropyl 
methylcellulose (HPMC) was kindly supplied by the Dow Chemical Company (New Milford, CT, 
USA).  Human vaginal epithelial cell line VK2/E6E7 (ATCC CRL-2616), human ectocervical 
epithelial cell line Ect1/E6E7 (ATCC CRL2-614) and human CD4+ T-cell line Sup-T1 (CRL-
1942) were obtained from ATCC. Keratinocyte-serum free medium (K-SFM), recombinant human 
epidermal growth factor and bovine pituitary extract were obtained from Life Technologies 
(Carlsbad, CA, USA). Trypsin-EDTA, penicillin/streptomycin solution and fetal bovine serum 
(FBS) were purchased from Gibco® Life Technologies (Burlington, ON, Canada). 
 
3.3.2. Fabrication of IVRs  
 PU HP-60D-35 and PU-93A pellets were dried overnight at 80C in an oven prior to the 
fabrication of IVRs. The pellets were melted using a hot-melt injection molder at 160C for PU-
60D and 140 C for PU-93A and then directed into a pre-heated mold (Cardatech, Alexandria, VA, 
USA) for the fabrication of macaque and human size reservoir-type IVRs (Figure 3.1). The outer 
diameter for the macaque-size IVRs is 25 mm, and the cross-sectional diameter is 5 mm. The wall 












Figure 3.1: Aluminum mold for the fabrication of reservoir-type IVR segments. The mold 
can produce segments for a large human size IVR (55 mm outer diameter and 5.5 mm cross-
sectional diameter) and a small macaque size IVR (25 mm the outer diameter and 5 mm the 
cross-sectional diameter). The wall thickness for both IVRs is 0.75 mm. IVR segments were 
fabricated using hot-melt injection molding of HP-60D-35 PU and HP-93A-100. 
 
3.3.3. HCQ/HPMC semi-solid preparation and HCQ extraction  
 The lumen of the IVR segments (PU-60D and PU-93A) was filled with HCQ/HPMC semi-
solid at a 1:1 ratio. Briefly, HCQ/HPMC was prepared by weighing 160 mg of HCQ and dissolving 
in 1.28 mL of distilled water. 160 mg of HPMC was then added to the dissolved HCQ and gently 
mixed with a spatula. The mixture was then transferred into a 5 mL syringe connected to a second 
syringe via tubing. The contents of the syringe were passed back and forth for 80 passes to allow 
homogenous mixing. Drug extraction was performed on random aliquots of the semi-solid mixture 
and analyzed using high-performance liquid chromatography (HPLC) to confirm homogeneity 
(See below for HPLC method). The HCQ/HPMC mixture (10±5 mg) was then diluted with 1 mL 
of distilled water in a microcentrifuge tube and vortexed at 2000 rpm at 4C overnight. The 
concentration of HCQ was then analyzed by HPLC. All downstream studies were done using the 
polymer presenting the best release profile.  
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3.3.4. HPLC Method  
 Quantification of HCQ was determined using a reversed-phase HPLC method as 
previously described (8). Briefly, a Shidmazu LC-2010A HPLC machine was used with a Waters 
Nova-Pak C18 column (4 m, 3.9 x 150 mm) in isocratic condition. The mobile phase included 
methanol, acetonitrile and 58 mM sodium phosphate dibasic containing 15 mM heptanesulphonic 
acid (4:22:74, v/v). The pH was adjusted to 3.1 using concentrated phosphoric acid. The flow of 
the mobile phase was maintained at 1 mL/min and the column at 25C for a run of 15 min with 40 
L of sample injected. The peak for HCQ appeared around 13 min.   
 
3.3.5. In vitro release studies  
HCQ-loaded IVR segments were sealed at both ends with silicone caps to prevent leakage 
and to mimic drug release from a “complete” IVR that does not have exposed ends. First, the 
release profiles of PU-60D and PU-93A were compared in sodium acetate buffer before choosing 
the suitable polymer for the rest of the studies. The segments were then sterilized using 70% 
isopropanol and dried in a biosafety cabinet overnight.  The segments were placed in 5 mL of 25 
mM of sodium acetate buffer (pH 4) and placed in an incubating shaker (37C; 100 rpm). Every 
24 ± 0.5 h, a sample of the release buffer was collected and buffer was replenished to maintain 
sink conditions. HPLC was used to evaluate the concentration of HCQ in each sample.  PU-60D 
presenting the suitable release profile, was used for the rest of the studies. To evaluate the system 
on bacteria, PU-60D segments were prepared and filled with HCQ semi-solid as described earlier 
and placed in 5 mL of MRS broth for a period of 24 days and placed in an incubating shaker (37C; 
100 rpm). The sampling and analysing were done as previously described. 
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3.3.6. Sensitivity test of HCQ on Lactobacilli, vaginal/ectocervical epithelial and immune 
cells 
 The microtitre broth dilution method was used to determine the minimum inhibitory 
concentration of HCQ on Lactobacillus crispatus and Lactobacillus jensenii as previously 
described with slight modifications [238, 239]. Briefly, bacteria were grown on MRS agar and one 
colony from the agar plates was transferred into 10 mL of MRS broth. The broth was incubated at 
37C under 5% CO2 for 24 h. The culture medium was diluted to achieve a concentration of 
approximately 105 CFU/mL. 100 L of 60 mg/mL of HCQ was added to each well in a 96 well 
plate and serial diluted to 1.8 mg/mL. Gentamicin (10 g/ml) and blank MRS broth were used as 
controls. 5 L of 105 CFU/mL of bacteria was dispensed in all the wells of the plate except one 
column containing blank MRS broth solution (sterility control and blank for the microplate reader). 
All plates were incubated at 37C at 5% CO2 for 24 h. Samples were analyzed at 580 nm using a 
microplate reader (Biotek, Winooski, USA).  
 Ect1/E6E7, VK2/E6E7 and Sup-T1 cells were seeded separately in 96-well plates at a 
density of 2.5 x 105 per well. After 2 h, 100 µL of HCQ or 200 µg/mL of N9 (N-9; positive control) 
were added into each well for 24 h. MTS reagent (40 µL) was added and the optical density of 
each well was analyzed at 490 nm after 1 h. Data were normalized and expressed as a percentage 







3.3.7. Cytotoxicity evaluation of IVR segments on lactobacilli and 
vaginal/ectocervical cell lines 
An elution assay was used to evaluate the cytotoxicity of drug-free IVR segments on 
bacteria. Briefly, 100 ± 0.5 mm IVR segments were sterilized in 70% isopropanol for 10 sec and 
dried in a sterile biosafety cabinet. The segments were transferred aseptically into 10 mL of sterile 
PBS and incubated at 37C for 1, 7, 15, and 30 days at 100 rpm in an orbital shaker. The 
supernatant was collected aseptically and filtered through 0.2 m syringe filters and stored at -
80C in 15 mL tubes until further analysis. 5 L (105 CFU/mL) of the diluted Lactobacillus 
crispatus and Lactobacillus jensenii were seeded in 96 well plates containing 100 L of medium 
at a ratio of 1:3 elution medium to growth medium (18). 100 L of the positive control (gentamicin 
10 µg/mL) and blank MRS broth solution were added as well. All plates were incubated at 37C 
at 5% CO2 for 24 h and samples were analyzed using a microplate reader at 580 nm.  
 IVR segments loaded with HCQ/HPMC were immersed in isopropanol for 10 min to 
prevent any contamination from external bacteria, and dried overnight in a biosafety cabinet. The 
segments were then placed in 5 mL of MRS broth for different time points (1, 3 and 7 days) at 
37C and shaken at 100 rpm in an orbital shaker. 100 L of broth containing elution media from 
HCQ-loaded IVR segments were distributed in a 96-well plate for different time points. 5 L of 
105 CFU/mL of Lactobacillus jensenii or crispatus were added to each well. Sterile MRS broth 
and MRS broth containing gentamicin (10 µg/mL) were used as controls. The 96-well plates were 
incubated at 37 C under 5% CO2 for 24 h and analyzed at 580 nm using a microplate reader.  
 IVR segments (150 ± 5 mg) were incubated in 10 mL of K-SFM medium for 30 days. 1 M 
acrylamide in K-SFM was used as positive control for inducing cell death while plain K-SFM 
medium was used as a negative control [68]. 100 µL of elution medium was used to treat 
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Ect1/E6E7 or VK2/E6E7 cells (2.5 x 105 cells per well) for 24 h followed by the addition of MTS 
reagent for 2 h. Optical density of each well was read at 490 nm and data was normalized to the 
negative control.  
 
3.3.8. In vitro evaluation of IVR segments on vaginal epithelial cell layer integrity 
 VK2/E6E7 were grown in K-SFM supplemented with 0.1 ng/mL of recombinant human 
epidermal growth factor, 0.05 mg/mL bovine pituitary extract, 44.1 mg/L calcium chloride and 
1% penicillin-streptomycin under 5% CO2 at 37C. The cells were transferred onto a cell culture 
polycarbonate membrane insert (pore size 1 m) at a density of 2 x 105 cells/insert. The cells were 
seeded in 0.3 mL of culture medium and the inserts were placed in 6-well plates containing 1 mL 
of medium. The cells were grown on the inserts for 3 days and the cell monolayer integrity was 
evaluated by measuring changes in trans-epithelial electric resistance (TEER) using a 
voltohmmeter (Millicell® ERS-2, Millipore). After reaching a TEER value of around 30  cm2 
cells were exposed to HCQ-free IVR segments, HCQ-loaded IVR segments, and 50 g/mL of free 
HCQ for 2 days. Untreated cells and cells treated with N-9 were used as controls.  
 
Statistical analysis. 
Data are presented as the mean ± standard deviation (SD). The n values refer to the numbers of 
replicates performed for each study. One-way analysis of variance was performed with all 






3.4. Results  
3.4.1. In vitro release studies 
 HCQ/HPMC (1:1 wt/wt) loaded  PU-93A IVR segments incubated in sodium acetate 
buffer (pH 4) at 37C shaken at 100 rpm, demonstrated a high burst release for the first three days 
and a drecreasing release for the remonaing days with ~ 3.8 mg of HCQ released in seven days 
(R2 value of 0.84). PU-60D presented a sustained release of HCQ over 24 days (Figure 3.3) and 
was used for the rest of the studies. The daily mean release of HCQ was approximately 17.013.6 
g/mL (39.19 M) of the initial 4 mg loading, with a cumulative release of 2041.80 180.21 
g/mL (4703.30 M) at day 24 (near zero-order release profile with a R2 value of 0.999). HCQ 
sulfate has a high water solubility ( >20 mg/mL as reported by Sigma Aldrich). We are releasing 
around 17 g/mL per day which is 1000x less than the saturation limit.  Release studies were also 
conducted in MRS broth at a pH of 6.2 (Figure 3.3). The release rate in MRS broth was 
significantly higher than in sodium acetate buffer (P-value <0.05)  with a daily mean release rate 
of 29.454.84 g/mL (67.86 M) and a cumulative release of 3534.5230.32 g/mL (8143.79 












Figure 3.2: Release study of HCQ in sodium acetate from PU-93A. (A). Daily release of 
HCQ from HCQ/K100M (ratio 1:1 wt/wt). Release studies were performed in 5 mL of 25 mM 
sodium acetate buffer (pH 4). (B) Cumulative release of HCQ from HCQ/K100M (ratio 1:1 








Figure 3.3: Release study of HCQ in sodium acetate and MRS broth. (A). Daily release of 
HCQ from HCQ/K100M (ratio 1:1 wt/wt) IVR segments for 24 days. Release studies were 
performed in 5 mL of 25 mM sodium acetate buffer (pH 4) or MRS broth (pH 6.2) and shaken 
on an orbital shaker at 37 °C, 100 rpm. (B) Cumulative release of HCQ from HCQ/K100M (ratio 








3.4.2. Sensitivity test of HCQ on Lactobacilli, vaginal/ectocervical epithelial and 
immune cells  
As shown in Figure 3.4A, 0.05 mg/mL of HCQ (approximately the amount of HCQ 
released daily from the segment) had no significant impact on the growth of lactobacillus jensenii 
or crispatus. Only at a concentration of 7 mg/mL of HCQ (which is more than 100-fold the 
concentration released daily) was there significant inhibition in growth of both bacteria. The 
positive control gentamicin (10 g/mL) inhibited 100% of bacterial growth.  
 Different concentrations of free HCQ were evaluated on the vaginal and ectocervical epithelial 
cell lines VK2/E6E7 and Ect1/E6E7, respectively, and on CD4+ Sup-T1 cells (Figure 3.4B). HCQ 
concentrations up to 0.01 mM did not elicit any significant cytotoxicity effects. Concentrations of 
0.1 mM significantly reduced Sup-T1 viability and concentrations ≥1 mM significantly reduced 

















Figure 3.4: The effects of 24 h HCQ treatment on vaginal normal flora, vaginal ecto-
cervical and epithelial cells and CD4+ immune cells. (A) Lactobacillus crispatus and jensenii. 
Bacterial growth was measured using a microplate reader set at 580 nm. The negative control 
(NC) was drug-free medium containing bacteria and positive control (PC) was medium 
containing gentamicin (10 g/mL). Data represent mean +/- S.D.; N=4; *P<0.05 vs NC. (B) 
Vaginal epithelial cells VK2/E6E7, ectocervical epithelial cells Ect1/E6E7, and CD4+ T-cells 
Sup-T1. NC consists of cells cultured in drug-free medium and PC consists of 200 g/mL N-9. 
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3.4.3. Cytotoxicity evaluation of IVR segments on lactobacilli and 
vaginal/ectocervical epithelial cell lines 
Drug-free IVR segments had no significant impact on the growth of Lactobacillus jensenii 
and crispatus after incubation for 30 days (Figure 3.5A) and on the viability of VK2/E6E7 and 
Ect1/E6E7 cells after 30 days when compared to controls (Figure 3.5B). 
HCQ released from the IVR segments significantly reduced the growth of Lactobacillus crispatus 
after day 3 and 7 but no significant changes in the growth of Lactobacillus jensenii was observed 




































Figure 3.5: Elution essay on Lactobacillus crispatus and jensenii and vaginal cells VK2/E6E7 
and Ect1/E6E7 . (A) Lactobacillus crispatus and jensenii treated with elution media from drug-
free IVR segments incubated in culture medium (ratio 1:3 v/v) for 24 h. Bacterial growth was 
measured using a microplate reader set at 580 nm. The negative control (NC) consists of culture 
medium containing bacteria and positive control (PC) consists of medium containing gentamicin 
(10µg/ml). Data represents mean +/- S.D.; N=3; *P<0.05 vs NC (B) Cell viability evaluation of 
VK2/E6E7 and Ect1/E6E7 after treatment with drug-free elution media. NC consists of cells 
treated with blank cell culture medium and PC consists of 1M acrylamide prepared in culture 
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Figure 3.6: Cytotoxicity study from HCQ released from IVR segment on Lactobacillus 
crispatus and jensenii. Lactobacillus crispatus and jensenii treated with media for 24 h containing 
HCQ released from drug-loaded IVR segments at various time points. Bacterial growth was 
measured using a microplate reader set at 580 nm. The negative control (NC) consists of bacteria 
treated with drug-free medium and the positive control (PC) consists of bacteria treated with 
medium containing gentamicin. Data represents the mean +/- S.D.; N=4; *P<0.05 vs NC. 
 
3.4.4. Assessment of transepithelial electrical resistance (TEER) of VK2/E6E7  
 The mean TEER value of an intact monolayer of VK2/E6E7 cells was approximately 
30.551.7 Ω cm2, which is comparable to previously reported values [240]. Figure 3.7 reports the 
TEER values after treatment with free HCQ (50 g/mL), drug-free IVR and HCQ-loaded IVR 
containing 1 mg/mL of HCQ.  No significant differences in TEER were observed with any of the 
treatment groups in comparison to the negative control after 48 h. The positive control (N-9) 
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Figure 3.7: Evaluation of TEER on a monolayer of VK2/E6E7 cells. The cells were treated 
with free HCQ (50 g/mL; 115.2 M), drug free IVR segments and HCQ eluted from an IVR 
segment for 48 h. Drug-free medium was used as negative control (NC) and N-9 (1 mg/mL) was 




 The FGT is becoming an important site for both local and systemic drug delivery 
particularly for the prevention of sexually transmitted infections eg. intravaginal microbicides. 
Benefits of intravaginal delivery include higher drug concentrations locally and a reduction in 
systemic toxicity. As a result, there is an urgent need to develop an effective and safe microbicide 
that can prevent HIV-1 infection.  Damage to the vaginal epithelial surface due to certain chemicals 
and drug carriers can cause inflammation of the FGT [241, 242]. Numerous studies have shown 
that inflammation within the FGT can increase the risk of HIV acquisition, an issue observed with 


















microbicides have focused on the induction of inflammation in vaginal epithelial and immune cells 
[245]. There is currently a lack of studies evaluating the impact of microbicides on the natural flora 
present in the FGT. Among the normal flora that will protect the FGT, lactobacilli are the main 
type of bacteria that set the balance between pathogenic bacteria and the normal flora. A decrease 
in lactobacilli encourages an overgrowth of pathogenic bacteria and can lead to inflammation [121, 
246, 247]. For example, studies have shown an increased risk of HIV infection in women with 
vaginitis and susceptibility to various sexually transmitted diseases [243-246]. Therefore, it is very 
important to assess the toxicity effects of microbicides on lactobacilli as well as their effects on 
vaginal epithelial cell monolayer integrity, to ensure that the microbicides do not disrupt the 
complex microenvironment. 
 HCQ is approved for the treatment of malaria, systemic lupus erythematosus, and 
rheumatoid arthritis. A number of studies have also demonstrated the direct anti-viral activity of 
HCQ against HIV [186, 190]. Furthermore, HCQ is capable of decreasing the activation of T-cells, 
reducing the number of target cells for HIV infection [184]. Two different medcal grade polymers 
were evaluated for their release profiles. PU-93A which has 100% percent water swallibilty 
released almost 100% of HCQ loaded in 7 days. The PU-93A  presented a busrt release for the 
first 3 days due to high water infiltration into the polymer causing the polymer to swaell and release 
the payload (Figure 3.2). We were able to obtain sustained release of HCQ from PU-60D IVR 
segments for up to 24 days in sodium acetate buffer and in MRS broth. The greater release 
observed in MRS broth versus sodium acetate buffer may be due to the high protein-binding 
capacity of HCQ itself [248]. The protein and lipid components present in  MRS broth could act 
as a sink for HCQ during the release studies [248]. A study has shown that 4.34 μg/mL (10 μM) is 
capable of suppressing early T-cell activation [186]. In the same study, a higher concentration of 
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up to 100μM (43.4μg/ml)   has been used to induce the IQ state in T-cells and was found to be safe 
[186]. The daily concentration released (Figure 3.3 A) from our IVR system was within the 
necessary therapeutic concentration range (4.34 g/mL) [249]  to induce IQ. To evaluate the safety 
of HCQ on lactobacilli, we treated the most common type of lactobacillus found in the FGT with 
different concentrations of HCQ. Lactobacillus crispatus and jensenii are the main strains of 
vaginal flora that produce hydrogen peroxide with a respective production of 95% and 94% 
according to a study conducted by Antonio and colleagues [250]. The lactobacillus family also 
uses the glycogen present in the vaginal tract to produce lactic acid to maintain an acidic vaginal 
environment (pH 4.2 – 5) [238]. The highest daily concentration of HCQ released in MRS broth 
from our reservoir IVR segment was nearly 35-fold lower than the highest concentration tested in 
the current study (1 mg/mL), which had no significant impact on bacterial growth (figure 3.4A). 
Concentrations higher than 1 mg/mL significantly inhibited the growth of both strains, which could 
be attributable to the bacteriostatic effects of HCQ [251]. Therefore, the level of HCQ released 
from our device is significantly lower than the levels that inhibit the growth of lactobacilli but is 
high enough to elicit a therapeutic effect within the FGT.  
 We have also evaluated the impact of drug-free IVR on bacterial growth. This is important 
to ensure that there is no degradation or unreacted polymer products leaching out of the IVR with 
time. Based on our results, drug-free IVRs had no significant impact on the growth of lactobacilli 
(Figure 3.5A). Although we have shown that free HCQ and drug-free IVRs have no significant 
impact on the growth of lactobacilli individually, it is unknown whether HCQ released from IVRs 
may have a significant effect. In our studies, HCQ-loaded IVR segments that were immersed in 
MRS broth for up to 7 days had no significant impact on Lactobacillus jensenii but there was a 
slight decrease in the growth of Lactobacillus crispatus with 3-day- and 7-day-immersed samples. 
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One possible reason for this observation may involve the higher levels of HCQ accumulated within 
the 3-day and 7-day MRS broth samples [251]. In the current study, IVR segments were incubated 
in broth medium for up to 7 days without changes in the broth medium. As a result, HCQ released 
from the IVR segments accumulated in the MRS broth during the entire 7-day study period (except 
when samples were collected on days 1, 3, and 7). Since normal FGTs produce vaginal secretions 
at 2 to 10 ml/day [252], HCQ released from the IVRs can be “washed out” of the FGT, resulting 
in lower vaginal HCQ concentrations.  
Furthermore, it was important to determine whether our IVR system would be cytotoxic to 
the surrounding epithelial tissues and the underlying mucosal immune cells of the FGT. Therefore, 
we evaluated the impact of our IVR system on the viability of vaginal and ectocervical epithelial 
cell lines and in a CD4+ T-cell line. HCQ concentrations of up to 4.34g/mL showed no significant 
effects (P<0.05) on the viability of VK2/E6E7 vaginal epithelial cells, Ect1/E6E7 ectocervical 
epithelial cells, or Sup-T1 immune cells, compared to the negative control. Drug-free IVR 
segments also demonstrated no significant impact on the viability of these three cell lines over a 
period of 30 days. 
Although we have shown that our HCQ-loaded IVR segments have no significant impact 
on the viability of vaginal/ectocervical epithelial cell lines, CD4+ T-cell line, and lactobacilli, it 
was not known whether there were any changes in the tight junctions of vaginal epithelial cells, 
which is a concern since this may increase the opportunities for viruses to penetrate the vaginal 
mucosal layer and to infect underlying immune cells [253]. As a result, we evaluated TEER values 
for VK2/E6E7 cell monolayers before and after exposure to HCQ alone, drug-free IVR segments, 
or HCQ-loaded IVR segments. All of the treatment groups demonstrated no significant effects on 
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TEER values after 48 h, compared to the negative control, suggesting that the vaginal epithelial 
cell monolayers were still intact. 
  This is the first study to evaluate the impact of HCQ-loaded IVRs on the growth of major 
strains of lactobacilli commonly found in the FGT. The amount of HCQ released daily was 
within the therapeutic concentration range necessary to induce T-cell IQ. The IVR system had no 
significant effects on the growth of Lactobacillus crispatus and jensenii, the viability of 
vaginal/ectocervical epithelial cells or immune cells, or the integrity of vaginal epithelial cell 
monolayers. These promising results support further investigation into the effectiveness of this 
new platform as a microbicide for the prevention of HIV-1 infection and other sexually 














Chapter 4: Segmented intravaginal ring for the combination 
delivery of hydroxychloroquine and anti-CCR5 siRNA 
nanoparticles as a potential strategy for preventing HIV infection 
 
 
Adapted from the following research article: 
Yannick Leandre Traore, Yufei Chen, Fernanda Padilla and Emmanuel A. Ho,  










Vaginal drug delivery has been shown to be a promising strategy for the prevention of 
sexually transmitted infections. Therapy delivered at the site of infection has many advantages 
including improved therapeutic efficacy, reduction in systemic toxicity and reduced potential for 
development of drug resistance. We developed a “smart” combination intravaginal ring (IVR) that 
will: 1) provide continuous release of HCQ to induce T-cell immune quiescence as the first-line 
of defense and 2) release nanoparticles containing anti-CCR5 siRNA only during sexual 
intercourse when triggered by the presence of seminal fluid as the second-line of defense. The IVR 
was capable of releasing HCQ over 25 days with a mean daily release of 31.17±3.06 µg/mL. In 
the presence of vaginal fluid simulant plus seminal fluid simulant, over 12x more nanoparticles 
(5.12 ±0.9 mg) were released over a 4 hr period in comparison to IVR segments that were 
incubated in the presence of vaginal fluid simulant alone (0.42 ±0.19 mg).  Anti-CCR5 siRNA 
nanoparticles were able to knockdown 83±5.1% of CCR5 gene expression in vitro in the CD4+ T-
cell line Sup-T1. The IVR system also demonstrated to be non-cytotoxic to VK2/E6E7 vaginal 
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Despite the efforts that have been made to date, HIV is still one of the leading causes of 
death in developing countries. More than 38 million people globally are living with HIV at the end 
of 2019 with women being more vulnerable due to biological and social-cultural factors. Reasons 
include the larger surface area of the female genital tract (FGT) in comparison to the male genital 
tract and the fact that after sexual intercourse, semen remains within the FGT for prolonged 
periods, increasing exposure to HIV [12, 254, 255]. Condoms remain as the best method for 
preventing HIV infection during heterosexual intercourse but unfortunately, in certain developing 
countries, women are not able to negotiate condom usage with their partners [256]. Furthermore, 
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due to the high rate of mutation by HIV, most conventional drugs are not effective due to the 
development of drug resistance. To reduce the development of multidrug resistance, therapy 
involving different classes of antiretrovirals is necessary [257]. However, this multidrug therapy 
can pose as a burden for patients especially when it must be taken daily. As one example, pre-
exposure prophylaxis (PrEP) consisting of tenofovir and emtricitabine, both reverse transcriptase 
inhibitors and marketed as Truvada, demonstrated high efficacy against HIV-1 [258]. 
Interestingly, a study has reported that low patient compliance to Truvada may result in the 
development of antiviral drug resistance [259, 260]. Hence, the necessity to develop an easy and 
effective therapy against HIV that does not require daily drug administration is required. A great 
strategy is to develop microbicides (self-administrated topical PrEP) that do not require much 
effort from the user [62]. An ideal microbicide would be one that is long-acting and is capable of 
delivering high dose of drug to the target site demonstrating therapeutic efficacy and low toxicity. 
A common challenge with microbicide development as observed in clinical trials is low patient 
adherence [261]. In addition, some microbicides have also elicited inflammation within the FGT 
resulting in increased HIV infection rates [243, 262, 263]. Different microbicides have been 
developed in the past several decades including vaginal gels, creams, suppositories, bio-adhesives 
and intravaginal ring [62, 264]. Intravaginal rings (IVRs) are an excellent alternative that can 
provide controlled and sustained release of an active ingredient within the FGT for an extended 
period [68]. IVRs have high acceptability amongst users and can be designed to deliver different 
active ingredients using the same ring [265, 266]. Furthermore, in a recent clinical trial, it was 
reported that placebo IVRs did not significantly induce an inflammatory response within the FGT 
of women suggesting that IVRs are safe for long-term use e.g. 28 days. [267]. In this study, we 
developed a dual-combination IVR system designed to prevent HIV infection by incorporating 
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two distinct approaches. The first strategy will be to induce an immune quiescent state using HCQ 
to reduce the number of HIV target cells within the FGT. Secondly, our IVR system will utilize 
gene therapy to knockdown the expression of CCR5 using small interfering RNA (siRNA) to 
reduce HIV binding to target cells. 
It has been shown that high CD4+ T-cell immune activation strongly correlates with HIV 
infection [268]. CD4+CCR5+ immune cells are the primary target cells for HIV. While activated, 
there will be an increase expression of cell surface markers such as HLA-DR, CD69, and CD38 
resulting in an increase in the susceptibility for HIV infection [188]. Studies have shown that HIV-
exposed seronegative women exhibit a unique immune phenotype called IQ whereby they exhibit 
a lower baseline of T-cell immune activation when compared to people that are at a greater risk of 
contracting HIV [188, 269]. HCQ, a widely available FDA approved immunomodulatory drug 
used for the treatment of malaria, systemic lupus erythematosus and rheumatoid arthritis, has been 
shown to reduce HIV viral loads and induce T-cell IQ [186, 270, 271]. By using an IVR to deliver 
HCQ in a sustained and controlled manner at the site of infection e.g. FGT, it will greatly reduce 
viral infection during sexual intercourse. The immunomodulatory properties of HCQ is a result of 
its ability to increase the pH of lysosomes within T-cells, interfering with the association of the 
invariant chain of the major histocompatibility complex class II molecule leading to their reduced 
ability to process antigens [272, 273] 
The second strategy will be to use siRNA directed against the CCR5 receptor expressed at 
the surface of T-cells. HIV will bind to CD4 and CCR5 receptors at the surface of T-cells to 
become internalized. Studies have shown that knocking down the CCR5 gene will prevent HIV-1 
infection. For example, the first patient to be completely “cured” from HIV received a bone 
marrow transplant from a donor who had a rare stem cell mutation that prevented the expression 
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of CCR5 on T-cells. Three months after the transplant, the patient was completely cured of HIV 
[274].  Recently, a second case of another patient following the same treatment using CCR5 
knockout stem cell transplant received from a donor was also cured of HIV [275]. Since it will be 
challenging to find sufficient donors for all HIV patients, using gene therapy to knockdown the 
CCR5 expression is a promising approach. In our study, we plan to deliver siRNA to target the 
CCR5 gene as a strategy for reducing HIV infection [276, 277]. siRNA being negatively charged 
cannot cross the cell membrane, and as a result, requires a carrier system such as solid lipid 
nanoparticles (SLN) to deliver siRNA into T-cells. SLNs were used due to its demonstrated 
biocompatibility and simplicity in terms of customization. For active targeted delivery to immune 
cells, SLNs were functionalized with anti-CD4 antibody. The attached CD4 antibody will facilitate 
binding of SLNs to the CD4 receptor on the surface of T-cells resulting in improved internalization. 
Our study aims to develop and characterize a segmented combination IVR delivery system 
consisting of one-half of the IVR loaded with HCQ and the second-half of the IVR to be coated 
with a pH-responsive film loaded with siRNA-encapsulated SLNs. It is expected that at normal 
vaginal pH (3.5-4.3) there will be no release of siRNA-loaded nanoparticles. During heterosexual 
intercourse, the vaginal pH becomes elevated (>6.2) due to the presence of seminal fluid [191]. As 
a result, it is expected that at pH>6.2, the IVR will provide rapid release of siRNA-nanoparticles 
while HCQ will be released continuously over time at both acidic and neutral pH to prevent 
immune activation of T-cells. This novel dual combination microbicide has the potential to 






4.3. Materials and Methods 
4.3.1. Materials 
Hydrophilic thermoplastic polyurethane (TecophilicTM HP-60D-35) was purchased from 
Lubrizol Advanced Materials (Cleveland, OH, USA). Eudragit L100 (methacrylic acid-methyl 
acrylate copolymer; anionic pH-sensitive polymer) was kindly donated by Evonik Industries 
(Essen, Germany). Hydroxypropyl methylcellulose (HPMC) K100M was donated by Dow 
Chemical Company (New Milford, CT, USA). Polyethylene glycol 400, NF (PEG-8) was acquired 
from Medisca (Saint-Laurent, QC, Canada).  HCQ was purchased from Thermo Fisher Scientific 
(Burlington, ON, Canada). CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) 
was purchased from Promega (Madison, USA). Glyceryl monostearate (molecular weight 358.56) 
was purchased from Sigma-Aldrich (Ontario, Canada). L--phosphatidylcholine (Soy-95%) 
(molecular weight 770.123 g/ mol) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE PEG 2000) were purchased from Avanti Polar Lipids 
(AL, USA). Polyvinyl alcohol (PVA; 31−50 kDa) and polyethyleneimine (branched, MW 25K) 
were obtained from Sigma-Aldrich (Ontario, Canada). Tris-EDTA was purchased from 
ThermoFisher Scientific (Ontario, Canada). 2-(N-morpholino) ethanesulfonic acid (MES) was 
purchased from Sigma-Aldrich (Ontario, Canada).  1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC; 200 mg/mL) N-hydroxysuccinimide (NHS; 275 mg/mL) were purchased 
from G-Biosciences (Missouri, USA). Anti-Human CCR5 siRNA (sense: 5'-
GUUCAGAAACUACCUCUUAdTdT-3' ; antisense: 3'-dTdTCAAGUVUUUGAUGGAGAAU-
5’) was purchase from Dharmacon (ON, Canada). Human CCR5 primers (Forward: 5’-
TTCATCATCCTCCTGACAATCG-3’; Reverse: 5’-GCCACCACCCAAGTGATCAC-3’) and 
human GAPDH primer (Forward: 5’-AAGAAGGTGGTGAAGCAGGCG-3’; Reverse: 5’-
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AGACAACCTGGTCCTCAGTGTAGC-3’) were purchased from Thermo Fisher (ON, Canada). 
E.Z.N.A.® RNA isolation kit was purchased from Sigma Aldrich (ON, Canada). PercCTa SYBR 
Green SuperMix and qScript™ cDNA were purchased from Quanta (ON, Canada). Anti-CD4 
antibody was purchased from Abcam (ON, Canada).  
 
4.3.2. IVR fabrication  
“Reservoir-type” and “matrix-type” IVR segments were fabricated from medical grade 
polyurethane (PU) HP-60-D-35 pellets using hot-melt injection molding (Medium Machinery, 
LLC, Woodbridge, VA, USA). Briefly, the pellets were dried overnight at 80ºC and loaded into a 
hot-melt injection molding. The PU was then melted inside the injection molder and injected into 
a custom-fabricated, pre-heated aluminum mold for the reservoir-type or matrix-type segment. The 
mold produced IVR segments with a 25 mm outer diameter and 5 mm cross-sectional diameter for 
the matrix type IVR. The reservoir type IVR had a wall thickness of 0.75 mm (Figure 4.1), 25 mm 
outer diameter and 5 mm cross-sectional diameter. The reservoir segment containing HCQ in the 
lumen was joined to the matrix segment using a butt-welding kit.  
 
4.3.3. HCQ loading in reservoir-type IVR  
HCQ was mixed with HPMC K100M to create a semisolid as described previously [69]. 
Briefly, 160 mg of HCQ was added to 1.28 mL of distilled water and mixed using the two-syringe 
method.  160 mg of HPMC K100M was added to the HCQ solution and mixed using the two-
syringe method. The semisolid was passed through the syringes 40 times to ensure homogeneity. 
The mixture was loaded into a reservoir-type IVR segment and both ends were sealed with resin 




4.3.4. Nanoparticle fabrication.  
SLNs encapsulated with siRNA (siRNA-NP) were prepared using a double-emulsion 
solvent evaporation technique as previously described with slight modifications [278]. We added 
50 µL of 0.372 mg/mL PEI to a solution containing 45 µL of Tris-EDTA buffer and 5 µL of 25 
µg siRNA. The mixture was incubated at room temperature for 15 min and mixed periodically. 
This aqueous solution was added slowly to 1.4 mL solution of glyceryl monostearate and L-α-
phosphatidylcholine dissolved in acetone and ethanol and sonicated for 30 s on ice using a probe 
sonicator. The double emulsion was formed by adding this mixture to 8 mL of 2% (w/v) PVA 
solution. We added 100µl of DSPE-PEG COOH from a 1.5mg/mL stock solution to the dispersion 
and stirred overnight. The organic solvents were then evaporated, and the siRNA-NPs were 
washed, and the encapsulation efficiency was determined. Anti-CD4 antibody was conjugated to 
the siRNA-NP by activating the carboxyl group on the nanoparticle’s surface by the addition of 
EDC and NHS at pH 6 for 60 min. The pellet was resuspended in 4.8 mL of 100mM of MES buffer 
and 100 µl of 27mg/mL of NHS and 100 µl of 10mg/mL of EDC were added. SLNs were vortexed 
and placed on an orbital shaker for 20min. SLNs were collected by centrifugation at 20,000g for 
40 min and the supernatant was discarded. The SLNs were resuspended in 1 mL of PBS and 100µl 
of 0.5µg/mL of anti-CD4 antibody was added to the suspension. The SLNs were placed on the 
orbital shaker for another 2 hours. The antibody-conjugated nanoparticles (siRNA-NP-Ab) were 
washed with distilled water, lyophilized, and stored at -20C until further analysis. Nanoparticle 
size and net surface charge were determined by light scattering using Zetasizer (Malvern). The 
antibody conjugation efficiency was performed following a method previously published by our 
lab [279]. Briefly, unconjugated antibodies from the supernatant were quantified using 
QuantiPro™ BCA assay (Sigma-Aldrich, USA). A volume ratio of 1:1 of BCA reagent and the 
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supernatant were mixed and incubate at 60°C for 1 hour. The sample was allowed to cool to room 
temperature and the reading was done at 505 nm on the microplate reader using BSA as standard.  
 
Figure 4.1: SLN preparation and conjugation to anti-CD4 antibody: PEI: Polyethylenimine, 
PC: L--phosphatidylcholine; GMS: Glyceryl monostearate 
 
4.3.5. pH-responsive coating preparation 
An optimised film formulation is necessary to achieve a uniform coating on the surface of 
the IVR. The coating should be able to stick to the IVR matrix when dried and not crumble or peel 
off when the IVR is compressed. For these reasons, we first evaluated the film forming capacity 
of Eudragit L100 and optimized the formulation that will work best for our IVR segments. Briefly, 
different percentages of Eudragit were dissolved in various organic solvents and evaluated for its 
film-forming properties. The solvents include isopropanol, dichloromethane, methanol, 
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dichloromethane:ethanol (50:50 v/v), and methanol:water (50:50 v/v). The mixture of organic 
solvent and Eudragit L100 was stirred at room temperature for at least 3 hr. After the complete 
dissolution of the polymer, PEG400 was added at different ratios (Table 2) and stirred for another 
10 min. In order to choose the best film formulation for the IVR coating, we performed a 
disintegration study to determine the rate of film disintegration. Briefly, 15 mg of Eudragit L100 
films containing PEG were incubated in PBS buffer (pH 7.2) for 20 min. Afterward, the remaining 
film was removed, dried in an oven at 37ºC and weighed. For the complete disintegration time, we 
monitored the film until there was complete dissolution with no visible particles in the buffer. 
Next, after deciding on the formulation that gave the best adherence and the fastest disintegration 
time, siRNA-NP-Ab was added to the formulation (3% Eudragit L100 plus 0.2 mL PEG 400), 
mixed and sonicated for 30 min without heat to obtain an aqueous dispersion and to remove air 
bubbles. A matrix IVR segment was coated with the mixture and dried at 40C for 15 min.  
  
4.3.6. In vitro release studies from the reservoir-type and matrix-type IVR segment  
Release studies were performed using reservoir-type IVR segments (19.6 ± 0.7mm) 
containing HCQ and K100M in the lumen as previously described [69] in vaginal fluid simulant 
(VFS; pH 4.2) following the recipe proposed by Owen et al. [252]. Briefly, IVR segments (19.6 ± 
0.7 mm) were placed in 5 mL of VFS at 100 rpm speed and 37oC. The amount of drug released 
was quantified using a reverse-phase HPLC method. Isocratic conditions were used with a Waters 
Nopak® C18 column (4µm, 3.9x150 mm) on Shimadzu LC-2010A HPLC system. The mobile 
phase consisted of 58 mM sodium phosphate dibasic buffer containing 15 mM of heptanesulfonic 
acid, acetonitrile and methanol at a volume ratio of 74:22:4 and the pH was adjusted to 3.1 with 
ortho-phosphoric acid. The flow rate was set at 1 mL/min and the wavelength of the detector was 
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set at 343 nm. The column was kept at room temperature and the HCQ retention time was 
approximately 8.4 min. We aim to achieve a targeted HCQ release of at least 4.3 µg/mL which is 
the minimum concentration required to induce T-cell IQ [249]. 
Separately, the pH-responsive coated matrix-type IVR segments were placed in two 
different release buffers. The first release buffer was VFS (pH 4.2) and the second buffer was a 
seminal fluid simulant (SFS; pH 8.2) prepared using a modified recipe of Rastogi et al. [280]. SLN 
containing coumarin 6 (C6) was prepared to help track NP release from the IVR segments. Briefly, 
a set of segments coated with Eudragit L100 containing C6 -SLN were placed in 4 mL of VFS. 
The volume of ejaculated seminal fluid is between 0.1 to 11 mL [281, 282]. Ejaculation volume 
less than 1 mL is considered hypospermia and more than 6 mL is considered hyperspermia. In this 
study we decided to evaluate the lowest normal ejaculation volume capable of changing the vaginal 
tract pH. Accordingly, another set of IVR segments were placed in 4 mL of VFS + 1 mL of SFS 
to simulate the presence of seminal fluid during sexual intercourse and placed inside a rotary 
shaker at 37C and set at 100 rpm.  The data was analyzed using a fluorescent microplate reader 
(SpectraMax M5).  
 
4.3.7. In vitro cytotoxicity studies of IVR containing NPs  
In vitro cytotoxicity was evaluated using the CellTiter 96® Aqueous One Solution Cell 
Proliferation assay. Briefly, vaginal epithelial cells VK2/E6E7 cells were cultured in K-SFM 
containing 0.1 ng/mL recombinant human epidermal growth factor, 44.1 mg/L calcium, 0.05 
mg/mL bovine pituitary extract and 1% penicillin-streptomycin. The cells were incubated at 37°C 
with 5% CO2. Separately, this medium was used to incubate a matrix IVR segment coated with a 
pH-responsive polymer. The segment in the medium was incubated at 37°C for 24 hrs at 100 rpm 
106 
 
in an orbital shaker. After almost reaching confluency, the cells were seeded onto 96-well plates 
at a density of 2.5x105 cells per well. The cells were then incubated for another 24 hrs and the 
medium in each well were replaced with the elution medium collected previously. 1M acrylamide 
was used as positive control and plain medium was used as negative control. The cells were 
incubated back for another 24 hrs followed by the addition of 20 µL of CellTiter 96® Aqueous One 
Solution Cell Proliferation assay reagent and incubated for another 2 hrs. The optical density of 
the wells was read using a microplate reader (SpectraMax M5) at 490 nm and data were normalized 
to the negative control value. Previously, we have shown that HCQ-loaded reservoir segments 
were non-cytotoxic [69]. 
 
4.3.8. In vitro CCR5 gene knockdown study 
In order to evaluate the efficacy on our SLN to deliver siRNA inside the cells and to know 
the minimum amount of siRNA needed to induce gene knockdown, we treated Sup-T1 cells in a 
96-well plate with only different concentrations of siRNA-NP-Ab. Briefly, SupT-1 cells were 
cultured in RPMI medium supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin incubated at 37°C with 5% CO2. The cells were seeded in 96 well-plate at a density 
of 2x104 cells/well. Each well was treated with 1.4 mg, 0.7 mg or 0.35 mg of siRNA-NP-Ab. The 
cells were incubated for 48 hrs at 37°C with 5% CO2. After incubation, the cells were washed with 
PBS and processed for mRNA extraction using the E.Z.N.A.® Total RNA Kit I.  1 µL of 100 ng  
of mRNA where mixed to 4 µL of cDNA supermix and 15 µL of RNase/DNase free water to make  
cDNA using qScript™ cDNA SuperMix in a thermal cycler (Bio-Rad C1000TM Thermal Cycler). 
The parameters for the thermal cycler used were 25°C for 5 min, 42°C for 30 min, 85 °C for 5min 
and hold at 4°C.  RT-PCR was performed using a mix of 10 µL of PerfeCTa SYBR Green 
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SuperMix, 2 µL of cDNA template, 2 µL of CCR5 forward and reverse primers (3µM).  GAPDH 
gene was used as endogenous control following the the same preparation as our gene of interest. 
The RT-PCR was using the Applied Biosystems StepOnePlus using the incubation times as 
presented below:  
95 °C for 5 min  
95 °C for 15 seconds 
60 °C for 30 seconds 
72 °C for 30 seconds  
72 °C for 15 seconds  
 
For the next study, Sup-T1 cells were seeded in a 24-well plate at a density of 0.8x105 cells 
per well. An insert was placed into each well and an IVR segment coated with a pH-responsive 
polymer containing siRNA-NP-Ab (sterilized using ultraviolet light for 1 hr) was placed into the 
insert. The IVR segments were suspended above the insert using a custom-designed holder made 
out of stainless steel wire (Fig. 1B). Negative control had an insert containing an IVR segment 
coated with blank NPs and another well with nothing but cells. The plate was placed on a shaker 
inside an incubator set at 2 rpm to allow the dissolution of the coating for 48 hrs at 37°C with 5% 
CO2. After incubation, we proceeded to the mRNA extraction and gene analysis as described 
above.  
Statistical analysis. 
Data are presented as the mean ± standard deviation (SD). The n values refer to the numbers of 
replicates performed for each study. One-way analysis of variance was performed with all 
results, with P values of <0.05 considered to be significant. 
 
 




4.4.1. IVR fabrication.  
A photo of the matrix and reservoir type IVR joined together is shown in Figure 4.1. A 
complete macaque-size IVR has a diameter of 25 mm, and a cross-sectional diameter of 5 mm. 
The reservoir-type IVR segment has a wall thickness of ~0.7 mm and a length of 19.6 ± 0.7 mm. 
The lumen of the reservoir was filled with HCQ mixed with K100M. The matrix IVR was coated 
with the modified pH-responsive polymer containing siRNA-NP-Ab. Both segments were joined 






Figure 4.2: Segmented intravaginal ring (IVR).  (A) The picture depicts a segmented 
intravaginal ring (IVR) formed by combining a reservoir-type segment with a matrix-type 
segment. The size of the IVR (25 mm x 5 mm) is designed for implantation into the female 
genital tract of non-human primates. IVR segments were fabricated using hot-melt injection 
molding of HP-60-D-35 polyurethane pellets and joined by butt-welding. (B) schematic 
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4.4.2. NP fabrication.  
Table 4.1 summarizes the SLN size, net surface charge, and drug encapsulation efficiency. 
The mean size of siRNA-NP-Ab was around 265.3±15.7 nm with a polydispersity of around 0.2. 
The siRNA encapsulation efficiency was 79.63± 7.3% and the net surface charge was around -
26±3.4 mV. Drug-free SLN had an average size of 210.5±20.8 nm with a polydispersity of 0.2. 
The antibody conjugation efficiency was 26.35± 4.41 %.  
 
Table 4.1: CCR5 siRNA-encapsulated SLN size, zeta potential, and encapsulation 
efficiency. 









siRNA-NP-Ab 265.3±15.7 79.63± 7.3% -26±3.5 0.2 
Drug-Free SLN 210.5±20.8 _____ -15±4.3 0.2 
 
 
4.4.3. pH-responsive coating preparation 
It is important to determine whether or not the selected solvent was capable of dissolving 
Eudragit L100. Table 4.2 lists the different solvents that were evaluated for their ability to dissolve 
Eudragit L100 and their film-forming properties. Dichloromethane and dichloromethane:ethanol 
(50:50 v/v) were able to dissolve Eudragit L100 completely, but they also partially dissolved the 
polyurethane HP-60D-35. Isopropanol was able to dissolve Eudragit L100 and did not have any 
effects on the polyurethane. Table 4.3 summarizes the effects of varying amounts of Eudragit L100 
and PEG 400 dissolved in isopropanol on film formation properties. The usage of low amounts of 
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Eudragit L100 (3%) with low amounts of PEG 400 (0.1 mL) resulted in the formation of fragile 
and easy-to-break films. Too much PEG 400 (0.5 mL) hindered the film-forming capacity of 
Eudragit L100 resulting in a gel-like mixture.  As a result, 3% Eudragit L100 dissolved in 
isopropanol supplemented with 0.2 mL of PEG 400 was used for all downstream studies since it 
produced the most uniform film with the fastest disintegration time.  We observed rapid 
disintegration within the first 20 min (42%) followed by a reduced rate of disintegration for the 
next 2.5 h. Complete film dissolution was achieved in 3 h (Table 4.4).  Only the formulations 
capable of forming a uniform and flexible film were considered in Table 4.4 for the disintegration 
study. The use of higher amounts of Eudragit L100 (>3%) resulted in films with longer 
disintegration times (>5 h).  
 
Table 4.2: Eudragit L100 properties in different organic solvents and their impact on 
polyurethane.  
 





Solvents 1% 3% 5%   
Methanol:Water (50:50 
v/v) 
Insoluble Insoluble Insoluble No None 
Methanol Partially soluble Insoluble Insoluble No None 
Dichloromethane Soluble Soluble Soluble Yes Dissolved 
Dichloromethane:Ethanol 
(50:50 v/v) 
Soluble Soluble Soluble Yes Partially 
dissolved 
Isopropanol Soluble Soluble Soluble Yes None 
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Table 4.3: Impact of varying amounts of Eudragit L100 and PEG 400 dissolved in 
isopropanol on film formation.  
FILM FORMATION           
      
PEG 400 
(mL) 
      
EUDRAGIT 
(%) 
0 0.1 0.2 0.3 0.4 0.5 
3 Rigid film Rigid film Flexible  Gel state  Gel state  Gel state  
4 Rigid film Rigid film Rigid film Flexible  Gel state  Gel state  
5 Rigid film Rigid film Rigid film Flexible  Gel state  Gel state  
7 Rigid film Rigid film Rigid film Rigid film Flexible  Gel state  
 
 
Table 4.4: Eudragit L100 film disintegration time  
Eudragit/PEG 
PBS pH 4 PBS pH 7.2 
Disintegration time 
3%/0.2mL None <3 hours 
4%/0.3mL None >5 hours 
5%/0.3mL None >5 hours 
7%/0.4mL None >6 hours 






4.4.4. In vitro release  
Release studies were performed on reservoir-type IVR segments containing HCQ/K100M 
in VFS separately from the matrix type IVR. We previously published a study evaluating the 
release of HCQ from HP-60D-35 IVR segments in sodium acetate buffer [68]. In this study, release 
was evaluated in VFS which more closely represents the physiological environment. HCQ released 
from the IVR segment was sustained over 25 days with a mean daily release of 31.17±3.06 µg/mL 
following a near-zero release kinetic profile (R2=0.998) (Figure 4.2). Over the period of 25 days, 
19.81 ±1.3 % of the total amount loaded was released. The matrix-type IVR coated with the pH-
responsive polymer containing C6-SLN was introduced in two different buffers for the release 
study. After 4 h, the segment placed in VFS released 0.42 ±0.19 mg of C6-SLN while the IVR 
segment that was incubated in VFS supplemented with SFS buffer released 12x higher amounts 







                             
 
                        
  
Figure 4.3: HCQ release in VFS. (A) Daily release of HCQ from HCQ/HPMC-loaded (ratio 1:1 
wt/wt) IVR segments for 25 days. Release studies were performed in 5 mL of VFS (pH 4.2) and 
shaken on an orbital shaker at 37°C, 100 rpm. Data represents mean ± S.D.; N=4. (B) Cumulative 
release of HCQ from HCQ/HPMC-loaded (ratio 1:1 wt/wt) IVR segments for 25 days. Data 







Figure 4.4: Release of C6-SLNs in VFS and SFS.  Release study of C6-SLNs in VFS only and 
in VFS plus SFS to simulate the presence of seminal fluid during sexual intercourse. Data represent 
the mean ± SD (n = 4).  *P < 0.05 versus VFS.   C6: coumarin-6; VFS: Vaginal fluid simulant; 
SFS: Seminal fluid simulant.  
 
4.4.5. Determination of the in vitro cytotoxicity of IVR containing SLNs 
The safety profile of the reservoir-type IVR segment containing HCQ/K100M was 
previously evaluated and published [69]. As a result, we focused only on the second half of the 
IVR in this study. As shown in Figure 4.4, no significant cytotoxicity was observed in VK2/E6E7 
cells incubated with matrix-type IVR segments coated with the SLN-loaded pH-responsive coating 
































Figure 4.5: Cytotoxicity evaluation of IVR coated with Eudragit L100 on VK2/E6E7  
epithelial vaginal cells. The IVR segment was coated with 15 mg of Eudragit L100 film. PC: 
Positive control (1M acrylamide); NC:  Negative control (cell media). Data represents mean ± 
S.D.; N=4.   *P < 0.05 versus NC  
 
4.4.6. In vitro CCR5 downregulation study 
To evaluate the gene knockdown efficiency of the SLN containing siRNA, siRNA-NP-Ab 
were incubated directly with SupT-1 cells. Cells treated with 1.4 mg of siRNA-NP-Ab for 48 hours 
(containing approximately 5 µg of siRNA) were able to achieve close to 60% CCR5 gene 
knockdown in 96-well plate (Figure 4.5). IVR segments coated with 7 mg of siRNA-NP-Ab 
(containing around 21.25 µg of siRNA) was able to release enough SLNs to significantly reduce 
CCR5 gene expression by 83±5.1% in comparison to controls after 48 hours of incubation in SupT-

























Figure 4.6 Evaluation of CCR5 gene expression using real-time PCR. The T-cell line (Sup-
T1) was treated with various concentrations of siRNA-NP-Ab for 48 hr. Data represents mean ± 















































Figure 4.7: Evaluation of coated IVR segment on CCR5 knockdown. CCR5 gene knockdown 
in Sup-T1 cells incubated with IVR segments coated with pH-responsive Eudragit L100/PEG 
containing siRNA-NP-Ab (~19.09 µg of anti-CCR5 siRNA). Blank: Sup-T1 cells alone; 
Negative control: consists of the IVR segment coated with the pH-responsive polymer but with 
drug-free SLNs. Data represents mean ± S.D.; N=3. *P < 0.05 versus negative control.  
 
4.5. Discussion 
HIV continues to be a major global health concern particularly for women, who are 
disproportionally impacted due to biological and socio-cultural factors. Many of the current 
therapies fail due to low patient compliance and the development of drug resistance [283]. An IVR 
system that can provide prolonged drug release and is easily administered without the assistance 
of a healthcare practitioner, will increase patient adherence [117]. Furthermore, using two different 
strategies that prevent HIV access to its target cells will greatly reduce infectivity and the potential 




































induce a T-cell immune quiescent state within the FGT as the first-line of defense. During 
heterosexual intercourse, the second half of the IVR will rapidly release anti-CCR5 siRNA-NP-
Ab to reduce the expression of CCR5 as the second-line of defense. However, further evaluation 
of our IVR system is required to determine whether or not drug resistance will develop. 
HIV-exposed seronegative sex workers exhibit a low baseline of immune activation within 
the FGT [269]. It is believed that this immune quiescent state plays an important role in protecting 
against HIV infection. We decided to induce T-cell IQ using the immunomodulatory drug HCQ. 
It has been shown that HIV-exposed seronegative people exhibit low baseline immune activation 
with reduced expression of HLA-DR, CD38, CD69, and CCR5 on T-cells [188, 284, 285]. In our 
study, HCQ was able to cross the hydrophilic PU wall of the IVR segments while immersed in 
buffer. The PU HP-60D-35 has a water swellability of 35% of its mass. The influx of water inside 
the polymer will aid in the diffusion of HCQ. To further control the diffusion of HCQ, a rate-
controlling excipient HPMC was used. The concentration needed to induce IQ in vitro is ~4.3 
µg/mL [186, 286]. The IVR segment is capable of releasing at least 7 folds more than the required 
concentration to induce IQ.  We demonstrated in previous studies that HCQ released from HP-
60D-35 was safe in a rabbit model, in the presence of vaginal (VK2/E6E7) and cervical (ECT-
1/E6E7) epithelial cells, and in the presence of normal flora Lactobacillus jensenii and crispatus 
[69, 287]. The concentration of HCQ released in this study is significantly lower than the 
concentration reported that can induce cytotoxicity in vaginal cells (433.96 µg/mL) and 
Lactobacillus jensenii and crispatus (7 mg/mL) [69].  
The second half of the IVR segment was fabricated to release anti-CCR5 siRNA-NP-Ab 
at high pH. The anti-CCR5 siRNA was mixed with PEI prior to encapsulation into SLNs. We 
believe once, inside the cells, the siRNA can escape endosomal degradation via the proton sponge 
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effect imparted by the positively charged PEI [288]. PEI has been shown to aid in the condensation 
of siRNA improving its encapsulation efficiency and assisting in the proton sponge effect by 
rupturing endosomes due to osmotic swelling.  
To avoid unnecessary gene knockdown when it is not required, well-timed release of SLN 
is important. The release of SLNs can be triggered during sexual intercourse by the presence of 
seminal fluid inside the FGT. This can be achieved by using Eudragit L100 that will react with the 
change in pH environment due to the presence of seminal fluid. Eudragit L100 made of 
poly(methacrylic acid-co-methacrylate) is protonated and uncharged at acidic pH. At basic pH, it 
will become deprotonated and the negative charges repel themselves causing the polymer to swell 
[289, 290].  The swelling of the polymer leads to its disintegration and the release of the SLNs. 
For the fabrication of the pH-responsive film, we evaluated different solvents capable of dissolving 
Eudragit L100 (Table 1). The aim of this experiment was to find the most suitable solvent capable 
of dissolving only Eudragit L100 but not the PU matrix that it is coated on. Isopropanol appeared 
to completely dissolve Eudragit L100 and not have any visible effects on the PU HP-60D-35. 
Disintegration time of the pH-responsive film is also important since the rate of SLN release needs 
to be rapid during sexual intercourse. Since HCQ is continuously released to maintain T-cell IQ, 
it is assumed that this will provide sufficient time for the SLNs to be released, enter CD4+ T-cells 
and silence CCR5 gene expression to prevent infection. In a non-human primate study, the authors 
have shown that sufficient infection was established only after 4 days [291]. Studies have shown 
that cervicovaginal mucus within the FGT may hinder nanoparticles from reaching the underlying 
submucosa [292]. As a result, the SLNs we prepared were coated with PEG that will potentially 
enhance the mucus penetration ability of the particles as described by others [293]. Assuming there 
is no mechanical tearing of the vaginal epithelium during sexual intercourse, we expect our SLNs 
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to enter the target cells and knockdown CCR5 gene expression in less than 4 days. For the SLN 
release studies, C6, a hydrophobic fluorescent dye was used to monitor the SLNs. As expected, in 
VFS alone, very low amounts of SLN was released. To simulate sexual intercourse, 1 mL of SFS 
was added to the VFS. In a study by Fox et al., the authors measured changes in vaginal pH during 
sexual intercourse using radio-telemetry and found that low volumes of semen (1.5 mL) was 
capable of raising vaginal pH from 3.5 to 5.5 within 15 sec [294]. At higher volumes of semen (5 
to 6 mL) the vaginal pH can be raised from 4.3 to 7.2 in 8 sec [294]. For our studies, we used 1 
mL of SFS which was capable of raising the pH of VFS from 4.2 to 7.3. This volume was selected 
to mimic the lower range of ejaculated seminal fluid, which was sufficient in removing almost the 
entire pH-responsive coating on the IVR segment. Human seminal fluid has a high buffering 
capacity and can easily change the vaginal tract pH from acidic to neutral and basic [295, 296].  
In our studies, we determined that as low as 5 µg of siRNA was capable of knocking down 
gene expression by around 50%. This study also confirmed that there was sufficient uptake of SLN 
by Sup-T1 cells to significantly reduce CCR5 mRNA expression. It took 48 hrs for the siRNA to 
be released from the SLNs to induce gene knockdown. However further studies must be performed 
in vivo to evaluate how fast the SLNs will reach the submucosa and to determine its efficiency in 
preventing HIV infection [291].  For in vivo studies, it is possible that other surrounding cells e.g. 
vaginal epithelial cells, may uptake the SLN, as a result, functionalizing the SLN with anti-CD4 
antibody will improve targeted delivery to CD4+ T-cells. Lastly, we determined that the coated 
IVR segments were non-cytotoxic to VK2/E6E7 vaginal epithelial cells. We have previously 
shown that PU HP-60D-35 is stable under accelerated stressed conditions of 40°C and 75% relative 
humidity [68], but further studies are needed to confirm the stability of the pH-responsive coating 
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under the same conditions. Although room temperature may not affect the coating, it is unknown 
what impact countries with elevated climates and humidity may have.  
 
4.6. Conclusion 
To the best of our knowledge, this is the first study to combine the delivery of HCQ and 
gene therapy as a novel strategy for preventing HIV infection. We were able to deliver HCQ 
continuously for over 3 weeks and also rapidly deliver siRNA-NP-Ab only at elevated pH 
environments such as those simulating the presence of seminal fluid. We were able to achieve 
significant CCR5 gene knockdown in comparison to controls and the IVR segment was non-
cytotoxic towards vaginal epithelial cells. Overall, combining chemotherapy and gene therapy into 
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Chapter 5: Thermo-responsive hydrogels for reducing biofilm 













Chronic wounds are often associated with ulcers (diabetic, pressure, venous) and non-
healing infections [297]. They present a substantial economic burden to the healthcare system 
significantly reducing the quality of life and potentially leading to serious events such as limb 
amputations or premature deaths [297].  Unfortunately, this burden is also subjected to increase as 
the population ages and lifestyle diseases such as diabetes and obesity become increasingly 
prevalent. Currently, treatment of chronic wounds involves regular replacement of wound 
dressings and constant monitoring from a healthcare professional. Therefore, an ideal wound 
dressing would require infrequent changes providing wound-healing properties for a long duration 
of time. It would also be expected to be non-toxic, maintain a moist environment, protect the 
wound bed, and promote tissue proliferation [298].  
Covering the entire surface area of the body, the skin is the largest organ in the human body 
approximately comprising one-tenth of the body mass [299].  As the body’s only barrier to the 
external environment, it protects it against exogenous factors and pathogenic microorganisms 
[300]. Normally, the skin is able to restore its integrity after injury through a process involving 
hemostasis, inflammation, proliferation, and remodeling [301].  Wound healing is a complex 
process that can be interrupted by both local (oxygenation, infections, biofilms) and systemic 
factors (age, gender, ischemia, diseases, medication, alcoholism, smoking, immunocompromised 
conditions, nutrition) [301]. When certain conditions are not met, wounds that generally heal in 
between 4-6 weeks enter and remain in a pathogenic, inflammatory stage failing to progress 
through the normal healing process resulting in a chronic wound [302]. The inflammation stage is 
an important stage of the wound healing process playing an important role in removing infectious 
microorganisms. However, incomplete microbial clearance in chronic wounds can cause 
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prolonged inflammation that leads to elevated levels of pro-inflammatory cytokines and matrix 
metalloproteinases that degrade the ECM [301]. Thus, an imbalance of proteases and growth 
factors puts the wound in a chronic state leading to a wound that fails to heal.  
Bacterial biofilms also arise as a potential factor hindering proper wound healing. With 
over 90% of chronic wounds containing biofilms, the microenvironment of chronic wounds is 
optimal for bacterial growth [303].  Biofilms are characterized by bacteria encased in an 
extracellular polymeric substance (EPS) matrix with an altered phenotype in regard to growth, 
gene expression, and protein production. Biofilm formation is a multistep process involving 
surface adherence, attachment and accumulation [166]. Clinically, biofilm has been proven to 
delay healing in different types of chronic wounds. Being less metabolically active than other 
bacteria, biofilms hinder chronic wounds from being susceptible to antibiotic treatment, resistant 
to host immune responses and therefore slow tissue repair by stimulating chronic inflammation 
[304]. Therefore, the presence of biofilms in wounds is crucial to take into consideration when 
formulating a treatment plan. In this paper, biofilms of Staphylococcus aureus, a ubiquitous Gram-
positive bacterium was studied. S. aureus is a major bacterial human pathogen that causes a wide 
variety of clinical manifestation, and are often found on skin, mucous membranes. As well, it is 
also one of the most prevalent bacterial species identified in chronic wounds causing prolonged 
inflammation and healing failure [305]. 
Various wound dressing materials such as hydrogels, hydrocolloids, foams, and alginates 
are available [298]. Of all the different materials, hydrogels are the most attractive due to fluid 
absorbency, ability to form a protective barrier and provide a moist environment for skin 
regeneration. However, most hydrogels are limited with poor mechanical properties [306]. Thus, 
in an attempt to increase the attractive features and overcome the limiting properties, the hydrogel 
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was lyophilized (Xerogel), resulting in a scaffold with effective exudate absorbency, physical 
stability and prolonged protection barrier via slow degradability. The proposed hydrogel is 
composed of gelatin, chitosan and ascorbic acid and aims to meet all the needs for proper wound 
healing and fast recovery. 
Gelatin is a polymer derived from collagen; an abundant protein found in human 
connective tissue. It is commonly used in tissue engineering due to high abundance, low cost, 
biocompatibility, biodegradability and low antigenicity [307]. As wound dressing materials, 
gelatin contains peptide sequences recognized by cell integrin receptors for cell adhesion and the 
ability to form a nanofibrous structure biomimics the extracellular matrix essential for skin 
regeneration [307]. Although gelatin is not a replacement for the new collagen production in 
wound tissue, it can still form an environment attracting critical cells for wound healing and 
provide an alternative substrate for negative effectors such as free radicals and proteases [308]. A 
structural transition occurs from a helix to a coil at temperatures above 35°C, undergoing a solid 
to liquid phase change [309]. With an average skin surface temperature of an individual at room 
temperature being around 33°C, the hydrogel is able to slowly transform into liquid form [310].  
Compared to traditional dry gauze wound dressings that may cause further injury upon removal, 
dressings composed of gelatin being thermosensitive will liquify into a gel and allow convenient 
removal or wash off without causing further harm to the wound bed.  
Chitosan a β-1,4-linked polymer of glucosamine and a derivative of chitin was used as a 
crosslinker to improve the physical stability of the hydrogel [311]. In order to convert chitosan 
into liquid form, it was dissolved in 1M of ascorbic acid. Several studies have shown the efficacy 
of ascorbic acid inhibits the formation of S. aureus biofilms in chronic wounds [312]. Being a 
biocompatible hydrophilic cationic biopolymer makes chitosan suitable to deliver drugs [313].  As 
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well, its antimicrobial effects against a broad range of both gram-positive and negative bacteria as 
well as fungi can prevent wound contamination. Moreover, previous in vitro studies have 
demonstrated the antibacterial properties of chitosan NPs [313].  
Various wound dressings that have been developed each have distinct features that protect 
the wound and promote healing. However, as chronic wounds are multifactorial in etiology, in this 
article we investigated to create a multifunctional dressing ideal for wound healing. This dressing 
functions as a foam-like dressing that moderately absorbs wound exudate. Moreover, the film-like 
thickness provides flexibility, and the designed dressing will allow patients to place it in difficult 
areas. Upon contact with wound fluid and skin surface temperature of 33 degrees Celsius, the 
dressing transforms itself into a hydrogel capable of rehydrating dry wounds and allowing painless 
removal from the wound bed. 
 
5.2. Materials and Methods 
5.2.1. Materials  
The gelatin from bovine skin, chitosan, ascorbic acid, Resazurin sodium salt, coumarin 6, 
Tryptic Soy Broth and sodium chloride were purchased from Sigma-Aldrich (Ontario, Canada). 
Glyceryl monostearate (molecular weight 358.56) was purchased from Sigma-Aldrich (Ontario, 
Canada). ∝-L-phosphatidylcholine (Soy-95%) (molecular weight 770.123 g/ mol) was purchased 
from Avanti Polar Lipids (AL, USA). Polyvinyl alcohol (PVA; 31−50 kDa) was purchased from 
Sigma-Aldrich (Ontario, Canada). Staphylococcus aureus (ATCC 25923) subsp. aureus 
Rosenbach was purchased from ATCC (Virginia, USA). D-glucose monohydrate was purchased 




5.2.2. Solid lipid nanoparticles preparation.  
SLNs containing either our drug of interest (LL37 and vancomycin) or C6 were prepared 
using a double-emulsion solvent evaporation  technique described previously with modification 
[278]. Briefly, 10mg of L-phosphatidylcholine and 5mg of glyceryl monostearate and were 
dissolved in 700μL of acetone and 700μL of ethanol at 55°C. 100μL of 0.05mg/mL of C6 or 100 
μL of the drug mixture (200 µg of LL37 and 400 µg of vancomycin) solution  was added into the 
lipid mixture. A primary sonication was performed for 20 seconds by a microtip probe sonicator 
at amplitude 5. The resultant emulsion was then emulsified with an aqueous phase solution 
containing 10mL of chilled 2% poly vinyl alcohol (PVA) and sonicated for another 60 seconds. 
The SLNs were stirred overnight to evaporate the organic solvent. They were collected by 
centrifugation (20,000g, 40min, 4°C) and washed twice with autoclaved Milli-Q water to remove 
excess emulsifier and free drug.  SLNs were added to 30mg of perlitol dissolved in 1mL of 
autoclaved Milli-Q water and frozen overnight at -75°C. Then SLNs were lyophilized for 24hr. 
NP size and net surface charges were determined by light scattering using ZetaPALS 
(Brookhaven).  
 
5.2.3. Hydrogel preparation  
The fluid absorbing capacity of the hydrogel is one of the important criteria for maintaining 
a moist environment over the wound bed. For the preparation of the hydrogel, we used a method 
already published with slight modification [314]. Briefly, to make 6% gelatin hydrogel, 0.6g of 
gelatin Type-A powder was dissolved in distilled water heated at 30oC until the solution becomes 
clear (about 30min). For the hydrogel to be stable, we must introduce a cross-linking agent such 
as Chitosan. The amount of chitosan was carefully added to present a UCST of around 33oC.   
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To make the chitosan solution, 10mL of autoclaved milli-Q water was used to dissolve 1.7612g of 
ascorbic acid powder and continuously stirred for 30 min at room temperature to produce a solution 
of clear 1M of ascorbic acid. 0.2g of chitosan was added to the solution and stirred at room 
temperature for overnight to ensure complete dissolution.  1:1 ratio of 6% gelatin and 2% chitosan 
were mixed to form the hydrogel. NPs suspension is added to the mixture to have the hydrogel NP 
formulation. Hydrogels were frozen overnight at -75°C then lyophilized for 24hrs.  
 
5.2.4. C6 SLNs release study from hydrogel.  
Release study was conducted on PermeGear Franz cells, and 6 hydrogels were tested at 
once. In the Franz cells, Whatman cellulose acetate membrane filter (1.2μm, diameter 47mm) was 
installed between the donor and the receiver compartment. The lyophilized hydrogel where place 
in the donor chamber and cover with parafilm to prevent moisture from the air to be in contact 
with the sample. The receiver chamber was filled with distilled water. Three hydrogels were tested 
at 33°C and the other three were tested at room temperature 23°C. A sampling volume of 5mL 
every 20minutes was withdrawn for a total of 2 hours, after every sampling, the receptor chamber 
was replenished with fresh autoclaved milli-Q water. 200μL of the collected sample was dispensed 
in a 96-well plate, and a standard was made using lyophilized C6 SLN. Fluorescence was measured 
at the excitation wavelength of 485nm, emission wavelength of 538nm, and cut-off wavelength at 
530nm.  
 
5.2.5. Preparation of microtiter plate-based biofilm model 
The microtiter plate-based (MTP) systems are frequently used for biofilm model systems 
[315, 316]. This is a cheap and easy model to study biofilm and allowed to perform many tests 
simultaneously [317]. S. Aureus was used in our study to form the biofilm model. To be able to 
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form the biofilm the Tryptic Soy Broth (TSB) was supplemented with 2% Glucose and 4% NaCl. 
One colony of S. Aureus was inoculated in 10mL of fresh both and incubated at 37°C and shake 
at 100 rpm for 24 hours. From that, 100µl of a dilution to generate 108 CFU was transfer in tissue-
treated 96 wells microtiter plate. The plate was then incubated at 37°C for 24 hours.   The 
supernatant was then removed and the biofilm was rinsed to remove unbound cells.   
 
5.2.6. Quantification of the biofilm using crystal violet and resazurin assays 
The total amount of biofilm biomass formed can be assessed using the crystal violet (CV) 
assay. CV binds to negatively charged surface molecules and polysaccharides in the extracellular 
matrix. Briefly, after 24h incubation, the content of the microtiter plate was discarded and the wells 
were washed to eliminate non-adherent cells. Biofilm was fixed with 96% ethanol and stained with 
200µl of  0.05% CV for 5 min. The content of the plate was discarded again and the bound CV 
was solubilized with acetic acid before reading the absorbance using the microplate reader at 
570nm.  
Resazurin assay was used to determine the metabolic activities of the biofilm. It is a blue 
redox dye that can be reduced by viable bacteria in the biofilm. Briefly, non-adherent cells will be 
discarded from the microplate. 1 mg/mL of resazurin was in PBS. The solution was protected from 
light and stores at 4°C. 100 µl of 10µg/mL of resazurin was added into each well and blank 
resazurin was added to non-treated wells as blank control. The plate was then incubated at 37°C 
for 20 min.  The fluorescence was read using a microplate reader (SpectraMax M5) with excitation 





5.2.7. Biofilm treatment with SLNs containing LL37 and vancomycin  
The bacteria were diluted to a concentration of 107 CFU and dispense in 96-well plate.  The 
plate was incubated for 24h at 37oC to allow the formation of a mature biofilm. The biofilm was 
treated with 1, 3, and 6mg/mL of SLNs containing LL37/Vancomycin. The plate was incubated 
for 24h at 37oC. After the plate was rinsed gently in PBS to remove unattached and loosely attached 
bacteria and we proceeded with the biofilm evaluation using CV as described above. 
 
Statistical analysis. 
Data are presented as the mean ± standard deviation (SD). The n values refer to the numbers of 
replicates performed for each study. One-way analysis of variance or student t-test were 
performed on all results, with P values of <0.05 considered to be significant. 
 
5.3. Results 
5.3.1. Solid lipid nanoparticles preparation. 
Table 5.1 summarized the particle sizes of the SLNs containing LL37 and vancomycin, 
and also the encapsulation efficiency and the zeta potential. The mean particle size is 237.8±13.3 
for loaded SLN and 207.3±13.7 for drug-free SLN. The encapsulation efficiency for LL37 is 
67.45±6.7 and for the vancomycin is 59.1±7.4. The zeta potential for blank SLNs were -20±3.2 







Table 5.1: LL37-Vancomycin SLN characterisation.   










-18±2.1  0.21 
 
Vancomycin: 59.1±7.4  
Drug Free  207.3±13.7    -20±3.2 0.23  
 
5.3.2. Hydrogel preparation  
For the hydrogel preparation, we used gelatin type-A. First, we evaluated the phase 
transition of gelatin alone. As reported in Table 5.2, 3% of gelatin will take approximately 25 min 
at 33°C to completely liquify. Increasing the gelatin percentage also increases the liquefaction 
time. For example, 10% gelatin took up to 39 min to liquify. To have a better texture of the 
hydrogel and better control on the liquefaction, we formulated the gelatin mixed with Chitosan. 
Increasing the percentage of chitosan increase the liquefaction time. 0.6% chitosan formulated 
with 6% gelatin took 30 min to completely liquify, but 1% chitosan with 6% gelation took twice 
the time, 60 min for complete liquefaction (Table 5.3). As noticed with gelatin alone, increasing 
the percentage of gelatin with chitosan also increases the liquefaction time. 9% gelatin formulated 























Figure 5.1: Picture of lyophilised  3% gelatin at 25°C and at 33°C after 25 min.  
 
 
Table 5.2:  Gelatin hydrogel phase transition. 
 
3% Gelatin 5% Gelatin 10% Gelatin 

















Time required to 
liquefy at 33°C 
Viscous liquid (15 min) 
Completely liquid (30 
min) 
Liquid at 60 
min 
Liquid at 30 
min 
Stay jelly after 5 
hours   
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5.3.3. C6 SLNs release study from the gelatin-chitosan formulation.  
We performed the release study of SLN from the hydrogel at room temperature and also 
33°C which is the mean temperature of human skin. To be able to tract the SLN and quantify them, 
coumarin 6 was encapsulated with SLN. C6-SLNs were mixed with the hydrogel, lyophilized 
before performing the release using Franz diffusion cell. Figure 5.1 shows the release at 23°C and 
33°C for two hours. At both temperatures, the hydrogel will start releasing after been moisturized 
by the wound fluid. A higher release at 33°C is observable with a total of 78.62% released compare 
to 23°C with 65.24% released (Figure 5.2).  
 
 
Figure 5.2: Amount of C6 NP Released Over Time. Data represent the mean ± SD.; N=3 , P-
value < 0.05 compared to 23°C. 
 




Figure 5.3: Percentage cumulative release of C6-SLN over time. Data represent the mean ± 
SD.; N=3, P-value < 0.05 compared to 23°C. 
 
5.3.4. Quantification of the biofilm using crystal violet and resazurin assays 
We prepared a microtiter plate-based biofilm (MTP)-base model. First, we evaluated the 
concentration of bacteria needed in each well to form a sticky biofilm. Using crystal violet to 
quantify the biomass, Figure 5.3 shows 107 CFU/mL was an optimum concentration to form the 
biofilm. 108 CFU seems to be too much for the bacteria to form a proper biofilm.  
In order to evaluate the living bacteria inside the biofilm, we treated each well with Resazurin 






Figure 5.4: Assessment of S. aureus biomass using 0.05% crystal violet in a 96-well plate. 
Data represents the mean ± S.D.; N=3. 
 
Figure 5.5: Evaluation of living S.Aureus bacteria present in the biofilm using resazurin. Data 
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5.3.5. Biofilm treatment with SLNs containing LL37 and Vancomycin  
Prepared LL37/vancomycin-SLN was used to treat biofilm formed using 107 CFU/mL of 
S. Aureus in a 96-well plate. Figure 5.5 shows different concentrations of SLNs used to treat the 
biofilm included negative control which is only blank medium and positive control consisted of 
penicillin-streptomycin. The different concentrations of SLNs used slightly reduce the amount of 
biofilm but lesser than the positive control. Three different concentrations 1, 3, and 6 mg/mL with 
were used to treat the biofilms. 1 and 2 mg/mL slightly reduced the biofilm with a significant 
reduction observed with 6 mg/mL. The positive control significantly reduced the biofilm formation 
compared to the highest concentration of SLN used (6 mg/mL).  
 
 
Figure 5.6: Biofilm treatment with LL37/vancomycin-SLNs. Blank medium as negative control 
and penicillin-streptomycin as positive control. NC: Negative control=Broth only, PC: positive 
control= 400 units of penicillin/400 ug of streptomycin. Data represent the mean ± S.D.; N=3.        










































The wound dressing plays an important role in the wound healing process. Currently 
available dressings still present some challenges in helping with wound healing. An ideal 
wound dressing will consider some important points such as maintaining a moist environment 
for the wound bed and having the possibility to remove the excess fluid. Also, it is very 
important to have a dressing that is easy to remove, non-toxic, and can be applied for a long 
period of time [192]. Gelatin appears to be an ideal biomaterial, which depending on its 
formulation, can be used to maintain a moist environment for the wound, can be used as a 
scaffold for tissue reconstitution, is non-toxic and, can be easily removed since it will liquefy 
at high temperatures. More importantly, gelatin can be used as a drug delivery vehicle to help 
remove the bacterial infection commonly see with chronic wounds [318]. The biofilm present 
in chronic wounds prevents them to heal, it is of the utmost importance to remove the bacterial 
infection for immunocompromised patients mostly to expect a skin regeneration [319]. The 
biofilm presence in chronic wounds plays a critical role by prolonging the inflammatory phase, 
such as the excessive release of cytokines, the extended presence of neutrophils and 
macrophages, the changes in oxygen concentration, and the pH in the wound [166]. In this 
study, we developed a thermo-responsive hydrogel as a wound dressing capable of delivering 
SLN containing a combination of LL37 and vancomycin in an effort to remove the bioburden 
from chronic wounds to improve wound healing.  
We formulated a hydrogel using only gelatin and we evaluated how long different 
percentages of gelatin will take to liquefy at 33°C. As expected, increasing the percentage of 
gelatin from 3% to 10% also increased the liquefaction time from 25 min to 39 min (Table 2). 
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Gelatin has a triple helix configuration at room temperature and lower. Gelatin chains become 
disordered (coiled structure) while heated above 30 °C and becomes more liquid [320].  The 
transition between helix and coil depends on the temperature, pH, concentration, stress, solvent 
used, and the presence of cross-linking agents [320-322]. Unfortunately, gelatin alone has poor 
mechanical properties [323].  To improve the physical stability of gelatin, we introduced 
chitosan as a cross-linking agent. The cross-linking agent increases the time needed for a 
complete transition from gel to liquid (Table 3). Lyophilizing the final formulation gave the 
gelatin-chitosan a more spongy-like characteristic that improved the exudate absorbency and 
physical stability. The primary role of our formulation is to protect the wound surface, deliver 
drugs that will eradicate biofilm formation in chronic wounds, and allow easy removal of the 
dressing without re-opening the wound. LL37 is a member of the cathelicidin family and is a 
peptide that has been shown to play a major role in host defense and has been successfully 
used against S. aureus, one of the major bacteria constituting biofilms in chronic wounds [324, 
325]. LL37 alongside the antibiotic vancomycin have been shown to exhibit synergistic 
antibacterial effects against S. aureus [326]. LL37 is a peptide and vancomycin is a 
glycopeptide, both of which may be prone to degradation. As a result, encapsulating the drugs 
into SLN will protect the drugs and offer slow prolonged release. Furthermore, the nanoparticle 
will help penetrate the biomass and deliver the drug to the bacteria encased in the extracellular 
matrix [327]. The LL37-vancomycin SLN was loaded into the hydrogel and lyophilized. By 
lyophilizing the hydrogel, it became more absorbent and can quickly absorb massive amounts 
of water and trigger the release of SLN present within the matrix. Figures 1 and 2 show a higher 
release of C6-SLN (C6 was used to fluorescently track SLN release) at 33°C compared to room 
temperature due to the thermo-responsive behaviour of the hydrogel. The higher release of C6-
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SLN at room temperature might somewhat hide the thermo-responsiveness of the dressing 
suggesting a not adapted release experiment setup. Instead of using a Franz diffusion cell that 
content 5 mL of liquid in the receiver chamber which is in contact with the release membrane 
and the lyophilized hydrogel, a dryer environment would have been more adapted. The 
lyophilization dries the hydrogel by sublimation, removing the frozen water crystal under high 
pressure leaving enough pores in the hydrogel structure, thus the high water absorption 
capacity [328, 329]. Although we have a release at both temperatures, we still have a significant 
difference in the release up to 100 min. The overall cumulative amount of C6-SLN released at 
33°C was significantly different (P-value<0.05) from room temperature. A dryer environment 
should be used in the future for testing the thermo-responsiveness.  
In order to evaluate the efficiency of our SLN to break down the biofilm formation 
using S. aureus, was evaluated in 96-well plate (Figure 3 and 4) and LL37-vancomycin SLNs 
were used to treat the biofilm. Figure 6 shows the different concentrations of SLNs used to 
treat the biofilm and the quantification of the biomass after treatment. 1mg/mL and 3mg/mL 
of SLNs have no significant impact on biofilm formation. 6 mg/mL significantly reduced the 
biomass compared to the negative control (blank medium). In one SLN preparation, 
approximately 134.9 µg of LL37 and 236.4 µg of vancomycin were encapsulated into the 
nanoparticles.  Shurko et al., showed that 32 µg/mL of LL37 and 256 µg/mL of vancomycin 
was enough to inhibit the growth of ATCC S. aureus 25923 [194]. It is possible in our study 
that the slow release of the drug from SLN is not sufficient to break down the biofilm in 24 
hours. The limitation of the in vitro design makes it difficult to study longer periods since the 
bacteria will begin to die naturally due to a lack of nutrient replenishment. An increased amount 
of drug encapsulated will probably allow more drug release in 24 hours to have a major impact. 
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Those limitations will not necessarily reflect in vivo conditions since higher amounts of SLN 
can be used in the dressing and the release can be sustained for a longer period of time. A 
biofilm testing system with a continuous flow of medium would be more appropriate for longer 
duration experiments such as the flow displacement biofilm model system [317]. It is also 
possible that the small amount of LL37 released from the SLN was quickly degraded by 
aureolysin and V8 protease produced by S. aureus [330]. This suggests higher concentrations 
of LL37 might be necessary to have a bactericidal effect.  
  
5.5. Conclusion  
This study aimed to develop a thermo-responsive dressing containing LL37-vancomycin 
SLN to help break down the biofilm formation on chronic wounds. We successfully fabricated a 
gelatin-chitosan hydrogel and improve its physical characteristic by lyophilization. As expected, 
was very absorbent and also liquefy at higher temperature hence an easy removal process from the 
wound without reopening the wound. Future studies are needed to better test the thermo-
responsiveness of the system and complete characterisation of the system. We developed a 
microplate biofilm model and tested SLN containing LL37 and vancomycin on the system. The 
SLNs were able to reduce the biofilm formed but not to the extent expected. This study allows us 
to learn many limitations of our in vitro system and also revealed the opportunities to make the 
system better in future studies. Overall, we have a system that is capable of releasing SLN at high 
temperature and the SLNs containing LL37 and vancomycin was able to decrease the biofilm 





































 Significance of the study  
Drug delivery systems have been developed to administer a pharmaceutical compound in 
a controlled manner to achieve an optimized therapeutic effect. Topical drug delivery as opposed 
to parenteral route offer more opportunity to deliver different types of drugs and use different 
routes. For example, protein drugs have always been challenging to deliver because of their size 
and fast degradation. Using NPs the protein can be protected and delivered to the targeted organ. 
Drug delivery devices have been used for vaginal and anal drug delivery, skin permeation, nasal 
and pulmonary delivery.  Topical drug delivery systems have been largely developed as 
microbicides for HIV prevention and also as a component of chronic wound dressings. 
Unfortunately, even with many efforts made in developing different microbicides to fight HIV 
infection, many fail due to toxicity issues or lack of efficacy. A lot of research must still be done 
to understand how the drug delivery systems work and how we can optimize them to achieve the 
aspired goal. For that reason, we took a different approach to understand the different mechanical 
behaviors of vaginal films containing NPs used to prevent HIV. We explored how the presence of 
NPs within the matrix of the film can affect the film structure. We also fabricated and characterized 
IVRs, especially the safety of polyurethane on vaginal cells and vaginal normal flora. In an effort 
to improve therapeutic efficacy and potentially prevent drug resistance, we developed a dual-
segmented IVR system to deliver a chemotherapeutic agent along with siRNA. For the last half of 
the thesis, we investigated the usage of stimuli-responsive polymers to fine-tune how composition 
and delivery time can help minimize unnecessary drug release and toxicity when not needed. We 
used a pH-responsive polymer coating on the second half of our dual IVR system to deliver siRNA-
encapsulated-NPs only when the pH of the FGT changed from acid to basic during sexual 
intercourse due to the presence of seminal fluid. Most of the post-exposure or pre-exposure 
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therapies existing nowadays are still non-affordable in developing countries. For example, the 
brand name Truvada, one of the well-known pre-exposure and also post-exposure prophylaxis cost 
around USD $1,258 without any subvention from the government for one month of therapy for a 
single person [331]. More efforts have been made to develop cheaper generics of Truvada. For 
example, Canada has a more affordable generic under the name of Emtricitabine-Tenofovir that 
costs around CAD $250 for 30 tablets. Those prices are very high for people living in developing 
countries where there are more people infected by HIV. The goal of this study was to design a 
more affordable therapy with high patient compliance. The design of the IVR is a good idea to 
empower women to protect themselves especially in regions where they cannot negotiate for safer 
sexual intercourse. HCQ is a good choice of drug to help protect people but also to reduce the price 
of the overall therapy since widely available at a lower price. With the purpose to develop a more 
potent therapy to protect against HIV infection and prevent drug resistance, gene therapy was 
introduced into the IVR design. Although siRNA is more expensive now, gene therapy is a fast-
developing area of research and a cost-effective alternative will soon be developed. Although more 
studies must be done, if successful, this new platform might save a lot of lives and money for 
people living in developing areas.  
 Lastly, we explored another stimuli-responsive polymer for the development of a thermo-
responsive wound dressing capable of delivering NPs containing drugs only when applied on the 
skin to eradicate biofilm formation on chronic wounds for immunocompromised patients. As 
previously stated, the current chronic wound dressing design and therapies have their flaws. Today, 
the most effective way to treat chronic wounds in immunocompromised patients is by surgery. 
Chronic wound is a huge burden for all communities and requires high financial inputs. The goal 
of this study was to create an easy-to-use wound dressing that can be applied on the wound to 
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protect it and also to deliver drugs that can eliminate the bioburden and speed up the wound healing 
process. This is aiming to create a therapy less invasive than surgery but with high effectiveness 
and hopefully improve the overall patient life conditions.  
 
 Summary of results  
We evaluated how the presence of NPs in the matrix of vaginal films composed of PVA 
can affect its mechanical properties. PVA films for drug delivery are usually formulated with 
plasticizers that affect the mechanical properties of the film to make it more flexible. The 
introduction of NPs into the matrix of the film may affect the film properties in terms of molecular 
crosslinking within the matrix. The objective of this study was to evaluate the physico-mechanical 
properties of PVA films containing plasticizers and in the presence of different concentrations of 
NPs.  We found that the amount of PVA used in a film formulation and the ratio of PVA and 
plasticiser greatly affect the film disintegration time. The NPs within the film matrix did not 
significantly alter the film’s mechanical behavior. From this study, we learned how we can fine-
tune a film formulation to expect the desire NPs profile through the film disintegration. In this 
study, the fast decay of the fluorescence from the NPs during the release study explains the low 
cumulative release. A stable fluorophore must be used to obtain a better evaluation of the amount 
of particles released. Commercially available controls like N9 can be used for comparison. 
Vaginal films are good drug delivery systems but they cannot provide controlled and 
sustained drug release for prolonged periods of time e.g. >1 week. In fact, the fast disintegration 
time of the film suggests a more rapid release of the active ingredient. IVRs can be designed to 
provide sustained and controlled drug release, ultimately resulting in increased patient adherence 
[233]. We developed a reservoir-type IVR that released HCQ in a controlled manner for >14 days.  
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We focused on the safety of the device and drug not only on vaginal cells but also on vaginal flora 
that is crucial for the protection of FGT. Damage to the vaginal surface due to the drug delivery 
device can cause inflammation of the FGT resulting in an increase in HIV infection [243]. We 
were able to achieve a daily release higher than the minimum concentration needed to induce 
IQ(4.3µg/ml) and 35-fold lower than the highest safe concentration tested (1 mg/ml). This study 
demonstrated the safety of the polyurethane HP-60D-35 used to fabricate the IVRs and HCQ 
toward vaginal and ectocervical cell lines Vk2/E6E7 and ECT1/E6E7 and also on the normal 
vaginal flora Lactobacillus jensenii and Lactobacillus crispatus. This chapter resumes promising 
results about the safety of IVR segment containing HCQ, but further in vivo studies must be done 
to evaluate its potentials as microbicide to prevent HIV infection.  
In the following chapter, we designed a segmented IVR system capable of delivering two 
different therapies to prevent HIV infection. Using different therapies creates multiple obstacles 
to HIV replication and reduces the possibilities of mutations [332]. The IVR designed had two 
segments, the first segment is a reservoir-type segment containing HCQ and a rate-controlling 
excipient as discussed previously, and the second segment is a matrix-type IVR that is coated with 
a pH-responsive polymer containing siRNA encapsulated SLN. In this study, we are taking 
advantage of the design of a stimuli-responsive polymer for the right time delivery of the gene 
therapy. We were able to continuously HCQ for over 24 days. The second half of the IVR coated 
with a pH-responsive polymer released C6-SLNs only at high pH when SFS to the low pH VFS 
to simulate sexual intercourse. The siRNA-SLN-Ab released from the segment was able to 
knockdown the CCR5 gene expression in comparison to the negative control using drug-free SLN. 
As a control in future studies, scramble siRNA can be used to evaluate the effect of non-specific 
siRNA itself on the safety of cells and their potential implication in gene expression. We found 
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that the coated segment was non-cytotoxic to vaginal epithelial cell VK2/E6E7. We demonstrated 
here a system that can potentially prevent HIV infection and reduce the virus mutation rate.  
The last project in this thesis was to develop a thermo-responsive wound dressing to help 
improve the healing of chronic wounds of immunocompromised patients by delivering drugs to 
eliminate biofilm formation. The main feature of this hydrogel dressing is its capacity to liquefy 
at a high temperature (33ºC temperature of the skin) compared to room temperature. We found 
that hydrogels composed of gelatine alone liquefied faster than gelatin crosslinked with chitosan.  
We found that the formulation started to release C6-SLN upon absorbing the release buffer but 
more release was observed at 33 ºC compared to room temperature. We found that the highest 
concentration of LL37/vancomycin-SLN (6mg/mL) used to treat the biofilm was able to 
significantly decrease the biomass compared to the negative control. However, we also observed 
that the positive control consisting of penicillin-streptomycin was more efficient due to its rapid 
contact with the bacteria. In conclusion, we developed a thermo-responsive system capable of 
release SLNs at high temperatures and our LL37/vancomycin was able to decrease the biofilm 
formation. Further characterizations are needed for this system and animal studies are required to 
evaluate the efficacy.  
 
 Future directions. 
 Patient compliance and therapeutic efficacy should be the priority when developing a drug 
delivery system. Even if a drug delivery system is therapeutically performant, low user 
acceptability will hinder its effectiveness. While the intravaginal film is capable of rapid delivery 
of active compounds within the FGT, the design of an IVR is more appealing and more advantages. 
Studies have been done on user acceptability of some specific type of IVRs. To the best of our 
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knowledge, we still do not have such data for IVRs made from polyurethane HP-60D-35. Future 
studies have to look at the physical and mechanical properties of the IVR to make sure it is not too 
rigid causing injury to the FGT or easily expelled from the FGT. Although the three weeks release 
period makes sense taking into consideration the menstrual cycle, it would be ideal to have a long-
acting drug delivery device (>6 months) as we are seeing now with the development of patches 
and injectables to protect against HIV infection. In this thesis, we used hot-melt extrusion to make 
the IVRs. This technique is fast and can produce consistent IVRs. But every time we have to 
change the design, it will require the fabrication of new molds. The aluminum mold needs to be 
created by a machine shop and requires high precision. Furthermore, lots of polymers are lost in 
the void space during the hot-melt injection process.  In the future, using three-dimensional 
printing (3DP) will grant the possibility of producing different sizes and shapes of IVRs on the 
spot while generating minimal waste. The computer aid design (CAD) file used to 3DP the IVR 
can be easily modified in-house as necessary.  
 Although we observed interesting in vitro gene knockdown data, in vivo studies must be 
performed on lab-adapted animal models. Unfortunately, it is challenging to develop a rodent 
animal model that has an acidic FGT to evaluate our pH-responsive polymer. In the future, we can 
potentially use for example a Human microbiota-associated (HMA) mice of women normal flora 
developed by Wolfarth et al [333]. This model colonises the mouse genital tract with human 
normal microflora. We can take advantage of this acidic environment to test our pH-responsive 
coated IVR segments.  It will be interesting if this mouse model can be humanized and we can 
challenge with HIV to evaluate the efficacy of our system in vivo.  
We had many limitations while evaluating the thermo-responsive wound dressing. The 
thermo-responsiveness should have been tested in a less moist environment that is more similar to 
149 
 
human skin since the lyophilised hydrogel absorbed high quantities of release medium and 
triggered the release of NPs. The release study can be done using the thermo-responsive valve-
based delivery device with two valves describe by Dinarvand et al [334]. Also, the flow 
displacement biofilm model system can be used in the future for a more optimized biofilm 
susceptibility study. In this system, the medium flows continuously and nutrients are constantly 
replenished, and wastes are removed. This system will allow to better characterize the adherence 
of the biofilm and extends the antimicrobial testing period which will give more time to the NPs 
to deliver their cargo to act on the bacteria.   
Overall, in this thesis, I developed and characterised various drug delivery systems and 
demonstrated how they can be used as a microbicide to prevent HIV infection and as a wound 
dressing for eliminating biofilms and improving chronic wound healing. Further studies are 
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